AU769969B2 - Production of pluripotent granulocyte colony-stimulating factor - Google Patents

Description

-1-

AUSTRALIA

PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT

ORIGINAL

00 0 Name of Applicant/s: Actual Inventor/s: Address for Service: Invention Title: Kirin-Amgen, Inc.

Lawrence M. Souza BALDWIN SHELSTON WATERS MARGARET STREET SYDNEY NSW 2000 'PRODUCTION OF PLURIPOTENT GRANULOCYTE COLONY- STIMULATING FACTOR' Details of Original Application No. 52042/98 dated 13 January 1998 The following statement is a full description of this invention, including the best method of performing it known to me/us:- File: 30517AUPO00 W ^r A -la- PRODUCTION OF PLURIPOTENT GRANULOCYTE COLONY-STIMULATING

FACTOR

Technical Field The present invention pertains in general to hematopoietic growth factors and to polynucleotides encoding such factors. The present application pertains in particular to mammalian pluripotent colony stimulating factors, specifically human pluripotent granulocyte colony-stimulating factor (hpG-CSF), to fragments and polypeptide analogs thereof and to polynucleotides encoding the same.

The present application is a divisional of Australian Patent Application No.52042/98, which is incorporated in its entirely herein by reference.

Background Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common 15 general knowledge in the field.

The human blood-forming (hematopoietic) system replaces a variety of white blood cells (including neutrophils, macrophages, and basophils/mast cells), red blood cells (erythrocytes) and clot-forming cells (mega-karyocytes/platelets). The hematopoietic system of the average human male has been estimated to produce on the order of 4.5 X 101 granulocytes and erythrocytes every year, which is equivalent to an annual replacement of total body weight. Dexter et al., BioEssays, 2, 154-158 (1985).

It is believed that small amounts of certain hematopoietic growth factors account S. for the differentiation of a small number of progenitor "stem cells" into the variety of blood cell lines, for the tremendous proliferation of those lines, and for the ultimate differentiation of mature blood cells from those lines. Because the hematopoietic growth factors are present in extremely small amounts, the detection and 2 identification of these factors has relied upon an array of assays which as yet only distinguish among the different factors on the basis of stimulative effects on cultured cells under artificial conditions. As a result, a large number of names have been coined to denote a much smaller number of factors. As an example of the resultant confusion the terms, IL-3, BPA, multi- CSF, HCGF, MCGF and PSF are all acronyms which are now believed to apply to a single murine hematopoietic growth factor. Metcalf, Science, 229, 16-22 (1985).

See also, Burgess, et al. J.Biol.Chem., 252, 1988 (1977), Das, et al. Blood, 58, 600 (1980), Ihle, et al., J.Immunol., 129, 2431 (1982), Nicola, et al., J.Biol.Chem., 258, 9017 (1983), Metcalf, et al., Int.J.Cancer, 30, 773 (1982), and Burgess, et al.

Int.J.Cancer, 26, 647 (1980), relating to various murine growth regulatory glycoproteins.

S. The application of recombinant genetic techniques has brought some order out of this chaos. For 20 example, the amino acid and DNA sequences for human erythropoietin, which stimulates the production of erythrocytes, have been obtained. (See, Lin, PCT Published Application No. 85/02610, published June 1985.) Recombinant methods have also been applied to the isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor. See, Lee, et al., Proc.

Natl. Acad. Sci. (USA), 82, 4360-4364 (1985) and Wong, et al., Science, 228, 810-814 (1985). See also Yokota, et al. Proc. Natl. Acad. Sci. (USA), 81, 1070 (1984), Fung, et al., Nature, 307, 233 (19.84), and Gough, et al., Nature, 309, 763 (1984) relating to cloning of murine genes, as well as Kawasaki, et al., Science, 230, 291 (1985) relating to human M-CSF.

A human-hematopoietic growth factor, called human pluripotent colony-stimulating factor (hpCSF) or pluripoietin, has been shown to be present in the cul- 3 ture medium of a human bladder carcinoma cell line denominated 5637 and deposited under restrictive conditions with the American Type Culture Collection, Rockville, Maryland as A.T.C.C. Deposit No. HTB-9. The hpCSF purified from this cell line has been reported to stimulate proliferation and differentiation of pluripotent progenitor cells leading to the production of all major blood cell types in assays using human bone marrow progenitor cells. Welte et al., Proc. Natl. Acad. Sci.

(USA), 82, 1526-1530 (1985). Purification of hpCSF employed: (NH 4 2

SO

4 precipitation; anion exchange chromatography (DEAE cellulose, DE52); gel filtration (AcA54 column); and C18 reverse phase high performance liquid chromatography. A protein identified as hpCSF, which is eluted in the second of two peaks of activity in C18 reverse phase HPLC fractions, was reported to have a molecular weight (MW) of 18,000 as determined by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) employing silver staining. HpCSF was 20 earlier reported to have an isoelectric point of [Welte, et al., J. Cell. Biochem., Supp 9A, 116 (1985)] and a high differentiation activity for the mouse myelomonocytic leukemic cell line WEHI-3B D (Welte, et al., UCLA Symposia on Molecular and Cellular Biology, Gale, 25 et al., eds., New Series, 28 (1985)]. Preliminary studies indicate that the factor identified as hpCSF has predominately granulocyte colony-stimulat:ng activity during the first seven days in a human CFU-GM assay.

Another factor, designated human CSF-8, has also been isolated from human bladder carcinoma cell -line 5637 and has been described as a competitor of murine 125 I-labelled granulocyte colony-stimulating factor (G-CSF) for binding to WEHI-3B D' cells in a dose-response relationship identical to that of unlabelled murine G-CSF (Nicola, et al., Nature, 314, 625-628 (1985)]. Tnis dose-response relationship "ad 4 previously been reported to be unique to unlabelled murine G-CSF and not possessed by such factors as M-CSF, GM-CSF, or multi-CSF (Nicola, et al., Proc. Natl. Acad.

Sci. (USA), 81, 3765-3769 (1984)]. CSF-s and G-CSF are also unique among CSF's in that they share a high degree of ability to induce differentiation of WEHI-3B D' cells. Nicola, et al., Immunology Today, 5, 76-80 (1984). At high concentrations, G-CSF stimulates mixed granulocyte/macrophage colony-forming cells [Nicola, et al., (1984) supra], which is consistent with preliminary results indicating the appearance of granulocytic, monocytic, mixed granulocytic/monocytic and eosinophilic colonies (CFU-GEM.M) after 14 days incubation of human bone marrow cultures with hpCSF. CSF-s has also been described as stimulating formation of neutrophilic granulocytic colonies in assays which employed mouse bone marrow cells, a property which has been a criterion for identification of a factor as a G-CSF. On the basis of these similarities, human CSF-s has been identified 20 with G-CSF (granulocytic colony stimulating factor).

Nicola et al., Nature, 314, 625-628 (1985).

Based upon their common properties, it appears that human CSF-3 of Nicola, et al., supra, and the hpCSF of Welte, et al., sunra, are the same factor which could properly be referred to as a human pluripotent granulocyte colony-stimulating factor (hpG-CSF). Characterization and recombinant production of hpG-CSF would be particularly desirable in view of the reported ability of murine G-CSF to completely suppress an in vitro WEHI- 30 3B D leukemic cell population at."quite normal concentrations", and the reported ability of crude, injected preparations of murine G-CSF to suppress established transplanted myeloid leukemias in mice. Metcalf, Science, 229, 16-22 (1985). See also, Sachs, Scientific American, 284(1), 40-47 (1986).

To the extent that hpG-CSF may prove to be therapeutically significant and hence need to be available in commercial scale quantities, isolation from cell cultures is unlikely to provide an adequate source of material. It is noteworthy, for example, that restrictions appear to exist against commercial use of Human Tumor Bank cells such as the human bladder carcinoma cell line 5637 HTB9) which have been reported as sources of natural hpCSF isolates in Welte, et al.

(1985, supra).

Summary of the Invention According to the present invention, DNA sequences coding for all or part of hpG-CSF are provided. Such sequences may include: the incorporation of codons "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences which facilitate construction of readily expressed vectors. The present invention also provides DNA sequences coding for microbial expression of polypeptide analogs or derivatives of hpG-CSF which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues deletion analogs containing less than all of the residues specified for hpG-CSF; substitution analogs, such as [Ser 7]hpG-CSF, wherein one or more residues specified are replaced by other residues; and addition analogs wherein one or more amino acid residues is added to a terminal or medial portion of the polypeptide) and which share some or all the properties of naturally-occurring forms.

Novel DNA sequences of the invention include sequences useful in securing expression in procaryotic -6or eucaryotic host cells of polypeptide products having at least a part of the primary structural conformation and one or more of the biological properties of naturally occurring pluripotent granulocyte colony-stimulating factor. DNA sequences of the invention are specifically seen to comprise: the DNA sequence set forth in Table VII and Table VIII or their complimentary strands; a DNA sequence which hybridizes (under hybridization conditions such as illustrated herein or more stringent conditions) to the DNA sequences in Table VII or to fragments thereof; and a DNA sequence which, but for the degeneracy of the genetic code, would hybridize to the DNA sequence in Table VII. Specifically comprehended in part are genomic DNA sequences encoding allelic variant forms of hpG-CSF and/or encoding other mammalian species of pluripotent granulocyte colony-stimulating factor. Specifically comprehended by part are manufactured DNA sequences encoding hpG-CSF, fragments of hpG-CSF and analogs of hpG-CSF which DNA sequences may 20 incorporate codons facilitating translation of messenger RNA in microbial hosts. Such manufactured sequences may readily be constructed according to the methods of Alton, et al., PCT published application WO 83/04053.

Also comprehended by the present invention is that class of polypeptides coded for by portions of the DNA complement to the top strand human cDNA or genomic DNA sequences of Tables VII or VIII herein, i.e., "complementary inverted proteins" as described by Tramontano, et al., Nucleic Acids Res., .12, 5049-5059 30 (1984).

The present invention provides purified and isolated polypeptide products having part or all of the primary structural conformation continuous sequence of amino acid residues) and one or more of the biological properties immunological properties -7in vitro biological activity) and physical properties molecular weight) of naturally-occurring hpG-CSF including allelic variants thereof. These polypeptides are also characterized by being the product of chemical synthetic procedures or of procaryotic or eucaryotic host expression by bacterial, yeast, higher plant, insect and mammalian cells in culture) of exogenous DNA sequences obtained by genomic or cDNA cloning or by gene synthesis. -The products of typical yeast Saccaromyces Cerevisiae) or procaryote Escherichia coli (E coli)]host cells are free of association with any mammalian proteins. The products of microbial expression in vertebrate non-human mammalian and avian) cells are free of association with any human proteins.

Depending upon the host employed, polypeptides of the invention may be glycosylated with mammalian or other eucaryotic carbohydrates or may be non-glycosylated.

Polypeptides of the invention may also include an initial methionine amino acid residue (at position 20 Also comprehended by the invention are pharmaceutical compositions comprising effective amounts of polypeptide products of the invention together with suitable diluents, adjuvants and/or carriers useful in hpG-CSF therapy.

o Polypeptide products of the invention may be "labelled" by association with a detectable marker substance radiolabelled with 125I) to provide 00.' reagents useful in detection and quantification of human hpG-CSF in solid tissue and fluid samples such as blood or urine. DNA products of the invention may also be labelled 30 with detectable markers (such as radiolabels and non-isotopic labels such as biotin) and employed in DNA hybridization processes to locate the human hpG-CSF gene position and/or the position of any related gene family in a chromosomal map. They may also be used identifying human hpG-CSF gene disorders at the DNA level and used as gene markers for identifying neighbouring genes and their disorders.

Polypeptide products of the present invention may be useful, alone or in combination with other hematopoietic factors or drugs in the treatment of hematopoietic disorders, such as aplastic anemia. They may also be useful in the treatment of hematopoietic deficits arising from chemotherapy or from radiation therapy. The success of bone marrow transplantation, for example, may be enhanced by application of hpG-CSF. Wound healing bum treatment and the treatment of bacterial inflammation may also benefit from the application ofhpG-CSF. In addition, hpG-CSF may also be useful in the treatment of leukemia based upon a reported ability to differentiate leukemic cells. Welte, et al., Proc. Natl. Acad. Sci. (USA), 82, 1526-1530 (1985) and Sachs, supra.

According to a first aspect, the present invention provides an isolated polypeptide consisting only of part or all of the amino acid sequence 1-174 set forth in Table VII which: has one or more of the biological properties typical of naturallyoccurring human pluripotent granulocyte colony-stimulating factor (hpG- CSF) of the sequence set forth in Table VII; is a non-naturally occurring polypeptide; and S 20 is the product of procaryotic or eucaryotic expression of an exogenous DNA sequence.

According to a second aspect, the present invention provides a DNA sequence which codes upon expression in a procaryotic or eucaryotic host cell for a polypeptide product having at least a part of the primary structure and one or more of the biological properties of naturally-occurring pluripotent granulocyte colony-stimulating factor, said DNA sequence being selected from among: the DNA sequence set out in Table VII or the complementary stands thereof; DNA sequences which hybridize to the DNA sequences defined in or fragments thereof; and 8a- DNA sequences which, but for the degeneracy of the genetic code, would hybridize to the DNA sequences defined in or and which sequences code for a polypeptide having the same amino acid sequence.

According to a third aspect, the present invention provides a prokaryotic or eucaryotic host cell transformed or transfected with a DNA sequence according to the second aspect in a manner allowing the host cell to express said polypeptide product.

According to a fourth aspect, the present invention provides a DNA sequence coding for (Ala') hpG-CSF.

According to a fifth aspect, the present invention provides a biologically functional plasmid or viral DNA vector including a DNA sequence according to the second aspect.

According to a sixth aspect, the present invention provides a process for the production of a polypeptide having part or all of the primary structure and one or more of the biological properties of naturally occurring pluripotent granulocyte colonystimulating factor, which process is characterized by culturing under suitable nutrient conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA sequence according to the second aspect in a manner allowing the host cell to express said polypeptide, and isolating desired polypeptide products of the expression of DNA sequence.

According to a seventh aspect, the present invention provides a process for the 20 production of a polypeptide having the primary structure of human pluripotent granulocyte colony-stimulating factor, which process is characterized by culturing under suitable nutrient conditions, prokaryotic or eucaryotic host cells transformed or transfected with a DNA sequence set forth in Table VII in a manner allowing the host cells to express said polypeptide, and isolating desired polypeptide products of the 25 expression of the DNA sequence.

According to an eighth aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a polypeptide according to the first aspect and/or produced by the process according to the sixth or seventh aspect and a pharmaceutically acceptable diluent, adjuvant or carrier.

According to a ninth aspect, the present invention provides use of a polypeptide according to the first aspect for the manufacture of a medicament for providing hematopoietic therapy to a mammal.

8b According to a tenth aspect, the present invention provides use of a polypeptide according to the first aspect for the manufacture of a medicament for arresting proliferation of leukemic cells.

According to an eleventh aspect, the present invention provides a DNA sequence coding for a polypeptide analog ofhpG-CSF having one or more cysteine residues deleted or replaced by alanine of serine residues.

According to a twelfth aspect, the present invention provides a non-naturally occurring polypeptide product of the expression in a prokaryotic or eucaryotic host cell of a polynucleotide according to the eleventh aspect.

According to a thirteenth aspect, the present invention provides a biologically functional plasmid or viral DNA vector including a DNA sequence according to the eleventh aspect.

According to a fourteenth aspect, the present invention provides a prokaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to the thirteenth aspect.

According to a fifteenth aspect, the present invention provides a polypeptide according to the first aspect preceded by a methionine residue.

S•According to a sixteenth aspect, the present invention provides an isolated polypeptide having the hematopoietic biological properties of naturally occurring 20 pluripotent granulocyte colony-stimulating factor, said polypeptide having an amino acid sequence selected from the polypeptide sequences set forth in Table VII, or any allelic variants, derivatives, deletion analogs, substitution analogs, or addition analogs thereof, and characterized by being non-naturally occurring and by being the product of prokaryotic or eucaryotic expression of an exogenous DNA sequence.

25 According to a seventeenth aspect, the present invention provides a non-naturally occurring polypeptide consisting only of the amino acid sequence 1-174 set forth in Table VII.

According to an eighteenth aspect, the present invention provides a pharmaceutical composition comprising an effective amount of the polypeptide according to the fifteenth aspect or the seventeenth aspect and a pharmaceutically acceptable diluent, adjuvant or carrier.

8c Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

Numerous aspects and advantages of the invention will be apparent to those skilled in the art upon consideration of the following detailed description which provides illustrations of the practice of the invention in its presently preferred embodiments.

Brief Description of the Drawings The Figure is a partial restriction endonuclease map of the hpG-CSF gene accompanied by arrows depicting the sequencing strategy used to obtain the genomic sequence.

Detailed Description According to the present invention, DNA sequences encoding part or all of the polypeptide sequence of hpG-CSF have been isolated and characterized.

^o *o o go.

ooo 9 The following examples are presented by way of illustration of the invention and are specifically directed to procedures carried out prior to identification of hpG-CSF cDNA and genomic clones, to procedures resulting in such identification, and to the sequencing, development of expression systems based on cDNA, genomic and manufactured genes and verification of expression hpG-CSF and analog products in such systems.

More particularly, Example 1 is directed to amino acid sequencing of hpG-CSF. Example 2 is directed to the preparation of a cDNA library for colony hybridization screening. Example 3 relates to construction of hybridization probes. Example 4 relates to hybridization screening, identification of positive clones, DNA sequencing of a positive cDNA clone and the generation of polypeptide primary structural conformation (amino acid sequence) information. Example 5 is directed to the identification and sequencing of a genomic clone encoding hpG-CSF. Example 6 is directed to the construction of a manufactured gene encoding hpG-CSF wherein E.coli preference codons are employed.

Example 7 is directed to procedures for construction of an E. coli transformation vector incorporating hpG-CSF-encoding DNA, the use of the vector in procaryotic expression of hpG-CSF, and to analysis of i properties of recombinant products of the invention.

Example 8 is directed to procedures for generating analogs of hpG-CSF wherein cysteine residues are replaced by another suitable amino acid residue by means of mutagenesis performed on DNA encoding hpG-CSF.

Example 9 is directed to procedures for the construction of a vector incorporating hpG-CSF analog-encoding DNA derived from a positive cDNA clone, the use of the "vector for transfection of COS-1 cells, and the cultured growth of the transfected cells. Example 10 relates to physical and biological properties or recombinant polypeptide products of the invention.

10 Example 1 Sequencing of Material Provided By Literature Methods A sample (3-4ug, 85-90% pure of SDS, silver stain-PAGE) of hpG-CSF was obtained from Sloan Kettering Institute, New York, New York, as isolated and purified according to Welte, et al., Proc. Natl. Acad.

Sci. (USA), 82, 1526-1530 (1985).

The N-terminal amino acid sequence of this sample of hpG-CSF was determined in a Run #1 by microsequence analysis using an AB407A gas phase sequencer (Applied Biosystems, Foster City, California) to provide the sequence information set out in Table I below. In Tables I-IV single letter codes are employed, designates a residue which was not unambiguously determined and residues in parentheses were only alternatively or tentatively assigned.

TABLE I 1 5 10 S )-G-L-X-X-X A high background was present in every cycle of the run for which results are reported in Table I, indicating that the sample had many contaminating components, probably in the form of chemical residues from 30 purification. The sequence was retained only for reference use.

In Run a second sample (5-6 ug, -95% pure) was obtained from Sloan Kettering as for Run #1 and a sequencing procedure was performed as for Run This sample was from the same lot of material employed to generate Fig. 4 of Welte, et al., Proc. Natl. Acad. Sci.

11 (USA), 82, 1526-1530 (1985). The results are given in Table II.

TABLE II 1 5 10 15

L)-X-

Although more residues were identified, Run #2 did not provide a sufficiently long, unambiguous sequence from which a reasonable number of probes could be constructed to search for hpG-CSF DNA. It was calculated that at least 1536 probes would have been required to attempt isolation of cDNA based on the sequence of Table II. Again, contamination of the sample was believed to be the problem.

Accordingly, a third sample (3-5 ug, pure) was obtained from Sloan Kettering as above. This preparation was electroblotted after separation by SDS- PAGE in an attempt at further purification. Sequence analysis of this sample yielded no data.

25 Sequencing of Materials SProvided by Revised Methods In order to obtain a sufficient amount of pure material to perform suitably definitive amino acid sequence analysis, cells of a bladder carcinoma cell line 5637 (subclone 1A6) as produced at Sloan-Kettering were obtained from Dr. E. Platzer. Cells were initially cultured Iscove's medium (GIBCO, Grand Island, New York) in flasks to confluence. When confluent, the cultures 35 were trypsinized and seeded into roller bottles (1-1/2 flasks/bottle) each containing 25 ml of preconditioned 12 Iscove's medium under 5% CO 2 The cells were grown overnight at 370C. at 0.3 rpm.

Cytodex-1-beads (Pharmacia, Uppsala, Sweden) were washed and sterilized using the following procedures. Eight grams of beads were introduced into a bottle and 400 ml of PBS was added. Beads were suspended by swirling gently for 3 hours. After allowing the beads to settle, the PBS was drawn off, the beads were rinsed in PBS and fresh PBS was added. The beads were autoclaved for 15 minutes. Prior to use, the beads were washed in Iscove's medium plus 10% fetal calf serum (FCS) before adding fresh medium plus 10% FCS to obtain treated beads.

After removing all but 30 ml of the medium from each roller bottle, 30 ml of fresh medium plus FCS and 40 ml of treated beads were added to the bottles. The bottles were gassed with 5% CO 2 and all bubbles were removed by suction. The bottles were placed in roller racks at 3 rpm for 1/2 hour before reducing the speed to 0.3 rpm. After 3 hours, an additional flask was trypsinized and added to each roller bottle containing beads.

At 40% to 50% of confluence the roller bottle cultures were washed with 50 ml PBS and rolled for 25 min. before removing the PBS. The cells were cultured for 48 hours in medium A (Iscove's medium containing 0.2% FCS, 10- 8 M hydrocortisone, 2mM glutamine, 100 units/ml penicillin, and 100 ug/ml streptomycin]. Next, the culture supernatant was harvested by centrifugation 30 at 3000 rpm for 15 min., and stored at -70*C. The cultures were refed with medium A containing 10% FCS and were cultured for 48 hours. After discarding the medium, the cells were washed with PBS as above and cultured for 48 hours, in medium A. The supernatant was again harvested and treated as previously described.

13 Approximately 30 liters of medium conditioned by 1A6 cells were concentrated to about 2 liters on a Millipore Pellicon unit equipped with 2 cassettes having 10,000 M.W. cutoffs at a filtrate rate of about 200 mi/min. and at a retentate rate of about 1000 ml/min.

The concentrate was diafiltered with about 10 liters of Tris (pH 7.8) using the same apparatus and same flow rates. The diafiltered concentrate was loaded at ml/min. onto a 1 liter DE cellulose column'equilibrated in 50m Tris (pH After loading, the column was washed at the same rate with 1 liter of 50mM Tris (pH 7.8) and then with 2 liters of 50mM Tris (pH 7.8) with 50mM NaCl. The column was then sequentially eluted with six 1 liter solutions of 50mM Tris (pH 7.5) containing the following concentrations of NaCl: 100mM; 125mM; 150mrM; 200mM; and 300mM. Fractions ml) were collected, and active fractions were pooled and concentrated to 65 ml on an Amicon ultrafiltration stirred cell unit equipped with a YM5 membrane. This concentrate was loaded onto a 2 liter AcA54 gel filtration column equilibrated in PBS. The column was run at ml/hr. and 10 ml fractions were collected. Active fractions were pooled and loaded directly onto a C4 high performance liquid chromatography (HPLC) column.

25 Samples, ranging in volume from 125 ml to 850 ml and containing 1-8 mg of protein, about 10% of which was hpG-CSF, were loaded onto the column at a flow rate ranging from 1 ml to 4 ml per minute. After loading and an initial washing with 0.1M ammonium acetate (pH 30 7.0) in 80% 2-propanol at a flow rate of 1/ml/min. One milliliter fractions were collected and monitored for proteins at 220nm, 260nm and 280nm.

As a result of purification, fractions containing hpG-CSF were clearly separated (as fractions 72 and 73 of 80) from other protein-containing fractions.

HpG-CSF was isolated (150-300 ug) at a purity of about 14 85±5% and at a yield of about 50%. From this purified material 9 ug was used in Run an amino acid sequence analysis wherein the protein sample was applied to a TFA-activated glass fiber disc without polybrene.

Sequence analysis was carried out with an AB 470A sequencer according to the methods of Hewick, et al., J.

Biol. Chem., 256, 7990-7997 (1981) and Lai, Anal. Chim.

Acta, 163, 243-248 (1984). The results of Run #4 appear in Table III.

TABLE III 1 5 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro- Gin Ser Phe Leu Leu Lys Leu Glu- 20 Val Arg Lys Ile Gly Val Gly Ala Ala- Leu X X In Run beyond 31 cycles (corresponding to residue 31 in Table III) no further significant sequence information was obtained. In order to obtain a longer unambiguous sequence, in a Run 14 ug of hpG-CSF purified from conditioned medium were reduced with 10 ul of a-mercaptoethanol for one hour at 45*C, then thor- -oughly dried under a vacuum. The -protein residue was then redissolved in 5% formic acid before being applied to a polybrenized glass fiber disc. Sequence analysis was carried out as for Run #4 above. The results of Run are given in Table IV.

15 TABLE IV 1 5 Thr Pro Leu Gly Pro Ala Ser Set Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin- Val Arg Lys Ile Gin Gly Asp Gly Ala Ala Leu Gin Phe Lys Leu Gly Ala Thr Tyr Lys Val Phe Ser Thr (Arg) (Phe) (Met) -X- The amino acid sequence give in Table IV was sufficiently long (44 residues) and unambiguous to construct probes for obtaining hpG-CSF cDNA as described infra.

Examole 2 Amcng standard procedures for isolating cDNA sequences of interest is the preparation of plasmid- 25 borne cDNA "libraries" derived from reverse transcription of mRNA abundant in donor cells selected on the basis of their expression of a target gene. Where sub- •stantial portions of the amino acid sequence of a polypeptide are known, labelled, single-stranded DNA probe sequences duplicating a sequence putatively present in .the "target" cDNA may be employed in DNA/DNA hybridization procedures carried out on cloned copies of the cDNA which have been denatured to single stranded form.

Weissman, et al., U.S. Patent No. 4,394,443; Wallace, et al., Nucleic Acids Res., 6, 3543-3557 (1979), and Reyes, et al., Proc. Natl. Acad. Sci. (USA), 79, 3270-3274 16 (1982), and Jaye, et al., Nucleic Acids Res., 11, 2325- 2335 (1983). See also, U.S. Patent No. 4,358,535 to Falkow, et al., relating to DNA/DNA hybridization procedures in effecting diagnosis; and Davis, et al., "A Manual for Genetic Engineering, Advanced Bacterial Genetics", -old Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1980) at pp. 55-58 and 174-176, relating to colony and plaque hybridization techniques.

Total RNA was extracted from approximately 1 gram of cells from a bladder carcinoma cell line 5637 (1A6) using a guanidinium thiocynate procedure for quantitative isolation of intact RNA. [Chirgwin, et al., Biochemistry, 18, 5294-5299 (1979)].

The sterile aqueous RNA solution contained total RNA from the IA6 cells. To obtain only the messenger RNA from the total RNA solution, the solution was passed through a column containing oligodeoxythymidylate [oligo(dT)] (Collaborative Research, Inc., Waltham, Massachusetts. Poly-Adenylated (poly-A tails characteristic of messenger RNA adhere to the column while ribosomal RNA is eluted. As a result of this procedure, approximately 90 pg of poly-adenylated messenger RNA (poly-A mRNA) were isolated. The isolated poly-A messenger RNA was pre-treated with methylmercury hydroxide (Alpha Ventron, Danvers, Massachusetts) at a final concentration of 4 mM for minutes at room temperature prior to use in a cDNA reaction. The methylmercury hydroxide treatment denatured interactions of messenger RNA, both with itself and with contaminating molecules that inhibit translation.

Payvar, et al., J.Biol.Chem., 258, 7636-7642 (1979).

According to the Okayama procedure [Okayama, et al., Molecular Cellular Biology, 2, 161-170 (1982)], a cDNA bank was prepared using mRNA obtained 35 from IA6 cells. The cDNAs were then transformed by incubation into a host microorganism E.coli K-12 strain HB101 for amplification.

17 Example 3 Hybridization probes designed on the basis of the hpG-CSF amino terminal sequence of Table IV consisted of a set of 24 oligonucleotides each being 23 bases in length and containing three inosine residues.

The probe oligonucleotides were manufactured according to the procedure of Caruthers, et al., Genetic Engineering, 4, 1-18 (1982) and labeled with r- 32 P ATP by kinasing with polynucleotide kinase. The probe oligonucleotides, corresponding to the messenger RNA for residues 23-30 of the sequence of Table IV, are illustrated in Table V.

TABLE V hpG-CSF Probes 5' GC IGC ICC GTC ICC TG GAT TT 3

T

The assignment of neutrality to I's was based on the published work of Takahashi, et al., Proc. Natl.

Acad. Sci. (USA), 82, 1931-1935 (1985) and Ohtsuka, et al., J. Biol. Chem., 260, 2605-2608 (1985). However, inosine may have a destabilizing effect if base paired with a G or T. In Takahashi, et al., inosines may appear to have a neutral effect because they average out 30 as a group to near neutrality three having paired favorably with C and two not favorable to pairing with

T).

To test the effect of having I's base pair wi-th G's, control experiments were designed using an Nmyc gene sequence 'and clone. The sequences picked from the N-myc gene had the same overall G and C content at 18 the first two positions of each codon as was prescribed by the hpG-CSF prob-es. Thus, the N-myc test probes -were of the same length, contained I's in the same relative positions and had potentially the same average Tm (62- 66°C., not accounting for the 3 or 4 inosine residues included) -as the hpG-CSF probes.

Two sets of N-myc test probes were constructed according to the procedure of Caruthers, et al., supra. Set I, as illustrated in Table VI included: 1, a 23 mer with perfect match; 2, in which three third position C's were replaced with I's generating the worst possible case for adding I's; and 3, in which four third position C's were replaced with I's. The second set of test probes was designed to represent a more random distribution of inosine base pairs, that might give an overall neutral base pairing effect. Set II, as illustrated in Table VI, included: 4, containing two I's that will base pair with C's and one with a G; and identical to 4 with the addition of one more I:G base 20 pair.

TABLE VI N-myc Test Probes 1. 5 CAC AAC TAT GCC GCC CCC TCC CC 3 2. 5'CAC AAC TAT GCI GCC CCI TCI CC 3 0*6.0: 30 3. 5'CAI AAC TAT GCI GCC CCI TCI CC 3

L

4. 5'AAC GAG CTG TGI GGC AGI CCI GC 3 5AA CT TGI GGC AI CC C3 5AAI GAG CTG TGI GGC AGI CCI GC 3 19 Five replica filters containing N-myc DNA sequences and chicken growth hormone DNA sequences (as a negative control) were baked in a vacuum oven for 2 hours at 80C. prior to hybridization. All filters were hybridized as described in Example 4 for the hpG-CSF probes except the period of hybridization was only 6 hours. Filters were washed three times at room temperature then once at 45 0 10 minutes each. The filters were monitored with a Geiger counter.

The filter representing N-myc probe 3 gave a very weak signal relative to the other four probed filters and was not washed any further. After a 10 minute 0 C. wash, the Geiger counter gave the following percent signal with probe one being normalized to 100%: Probe 2, 20%; Probe 3 (45 0 Probe 4, 92%; and Probe 5, 75%. After a 55 0 C. wash, the percentages were: Probe 2, 16%; Probe 4, 100%; and Probe 5, 80%. A final wash at 60 0 C. yielded the following percentages: Probe 2, Probe 4, 90%; and Probe 5, Thus, in the presence of three I's, as in probes 2 and 4, up to a 60-fold difference in signal is observed as the theoretical Tm (I's not included in the calculation) is approached [based upon a worst case I base pairing (Probe 2) and a relatively neutral I base 25 pairing case (Probe The standardization information gained by the N-myc test hybridizations was utilized in washing and monitoring of the hpG-CSF hybridization as indicated below, to gauge the degree of confidence with which the results of less than stringent washing might be accepted.

Example 4 According to the procedure of Hanahan, et al., J. Mol. Biol., 166, 557-580 (1983), bacteria containing 20 recombinants with cDNA inserts as prepared in Example 2 were spread on 24 nitrocellulose filters (Millipore, Bedford, Massachusetts) laid on agar plates. The plates were then incubated to establish approximately 150,000 colonies which were-replica plated to 24 other nitrocellulose filters. The replicas were incubated until distinct colonies appeared. The bacteria on the filters were lysed on sheets of Whatman 3 MM paper barely saturated with sodium hydroxide (0.5M) for 10 minutes, then blotted with Tris (1M) for 2 minutes, followed by blotting with Tris (0.5M) containing NaCI (1.5M) for minutes. When the filters were nearly dry, they were baked for 2 hours at 80 0 C. in a vacuum oven prior to nucleic acid hybridization. [Wahl, et al., Proc. Natl.

Acad. Sci. (USA), 76, 3683-3687 (1979)]; and Maniatis, et al., Cell, 81, 163-182 (1976).

The filters were prehybridized for 2 hours at 0 C. in 750 ml of 10X Denhardt's, 0.2% SDS and 6X SSC. The filters were rinsed in 6X SSC, then placed four in a bag and hybridized for 14 hours in 6X SSC and Denhardt's. There was approximately 15 ml of solution per bag containing 50 x 106 cpm of 3 2 P-labeled S" probe (oligonucleotides).

After hybridization, the filters were washed three times in 6X SSC (1 liter/wash) at room temperature for 10 minutes each. The filters were then washed two times at 45 0 C. for 15 minutes each, once at 500 for minutes and once at 55 0 C. for 15 minutes using 1 liter S" volumes of 6X SSC. The filters were autoradiographed for 2 hours at -70 0 C. using an intensifying screen and Kodak XAR-2 film. On this autoradiograph, there were 40-50 positive signals detected including 5 very intense signals.

The areas containing the strongest five signals and an additional five positives were scraped from the master plates and replated for a secondary 21 screening using the same probe mixture under the same conditions. The wash procedure differed in that the high temperature washes consisted of two at 55oC. for minutes each and then one at 60°C. for 15 minutes.

Based on the N-myc probe study of Example 3, the final wash temperature in the second screening was raised because the aggregate melting temperature for the 24 23mers was 60-68 0 similar to that of the N-myc probes. Just after the second 55 0 C. wash, the filters were left damp and an autoradiograph was made. Comparison of this autoradiograph with a second autoradiograph taken for a similar period of time after a final wash at 0 C. showed that only two of the 10 clones being tested did not suffer a substantial loss in signal in rising from 55-60 0 C. These two clones were later shown to be of nearly identical lengths and restriction endoclease patterns. One clone designated Ppo2, was selected for sequencing.

Sequencing of the recombinant hpG-CSF cDNA clone, Ppo2, obtained by the above procedure was accomplished by the dideoxy method of Sanger, et al., Proc.

Natl. Acad. Sci. (USA) 74, 5463-5467 (1977). The single-stranded DNA phage M-13 was used as a cloning vector for supplying single-stranded DNA templates from 25 the double-stranded cDNA clones. The Sanger, et al., method revealed the sequence as set forth in Table VII accompanied by its amino acid translation and a complementary strand in the polypeptide coding region.

0 0 0000 S 0* 0505 TABLE V1I IlindII AG;CTTGGACfdAGCGGGGGGGGGGGGGGGGCGGGGGGGGGGGGCGGG [fNNNNN I Ala Ser GCC ACC CGC 'fcC dly Asp CCC GAT CCG CT A Giu Leu GAG CTG CTC GAC Ser Gin AGC CAG TCG OTC Gin Gly CAG CG GTC CCC -12 Leu Trp CTIG TG GAC ACC S.er Leu Pro TCC CTG CCC AGG GAC GGG Gly Ala Ala CCC GCA CCG CCC COT CC so Vil Leu Leu GTG CTG CTC CAC GAC GAG Ala Leu Gin GCC CTG CAG CGG GAC GTC ILeu Leu Gin CTC CTG CAG GAG GAC GTC -10 HIs

CAC

GTG

Gin

CAG

CTC

Leu

CTC

GAG

Gly

GGA

CCT

Leu

CTG

GAC

Ala Gcc

CGG

Ser Plie Leu Leu AGC TTC CTG C'rc TCG AAG GAC GAG Gin Giu Lys Leu CAG GAG AAG CTO GTC CTC TTC GAC Ilis Ser Leu Cly CAC TCT CTG GCC GTG AGA GAC CCC Ala Oly Cys Leu OCA GGCcTGC TTG COT CCC ACG AAC Leu Glu Gly Ilie CTG GAA GGG ATC GAC CTT CCC TAG -1 +1 Ser Ala Leu TrpTr Val Gin Clu Ala Thr AGT! OCA CTC TGG ACA GTG CAC GAA GCC ACC TCA COT GAG ACC TCT CAC GTC C'rr CGG TG Jli AI Lys Cys Leu MAG TGC TTA 'fTC ACG AN!' Cys Ala Thr TGT GCC ACC ACA CGG TGG Ile Pro Trp ATC CCC TGG TAG CCC ACC Ser Gin rLeu AGC CAA CTC TCO CTT GAG Ser Pro Glu TCC CCC GAG AGG GCC C'1'C Giu Gin Val GAG CMA GTG CTC OTT CAC Tyr Lys Leu TAC AAG CTG ATO TTC GAC Ala Pro Leu OCT CCC CTG CGA CCC GAC 00 Ilia Ser Oly CAT Add GCC GTA TCG CCC Pro Leu Gly Pro CCC CTG CCC CCT COG GAd CCG GGA A8pa I A rg Lys IleGin AGO AAG ATC CAd TCC TTC TAG GTC Cys Iial Pro Olu TGC CAC CCC GAG ACO OTO CCC CTC Ser Ser dye Pro ACC AGC TGC CCC TCG TCO ACO CCC Leu Phe Leu Tyr CTT TTC CTC 'rAC GMA AAO GAG ATG 100 Leu Cly Pro Thr Leu Asp Thr TTIG CC'r CCC ACC TTG GAC ACA AAC CCA (JGG TGG MAC CTrG TOT TABLE VII (cont'd.) Leu

CTG

GAC

Met

ATG

TAC

Arg

CC

CC

Arg c~c

CCC

Gin

CAC

GTC

Leui

CTG

CAC

Ala Pro GCC CCT CCC OCA Arg Ala CGG GCA CCC CGT Val Leu GTT CTA CAA GAT Asp

GAC

CTG

Ala.

CC

CCC

Gly

GCA

CCT

Arg

COC

C

110 Val1

GTC

CAC

130 Leu

CTG

CAC

150 Gly

CCC

CCC

170 is

CAC

CTG

Ala Asp Phe CCC GAC TTT CCC CTG AAA Gin Pro Thr CAG CCC ACC GTC CCC TG Val Leu Val CTC CTG CTT CAG GAC CAA Leu Ala Cmn 120 Ala Thr Thr Ile Trp Gin Gin Met Clii Clii Leu Gly CCC ACC ACC ATC TOG CAG CAG ATG GAA GAA CTG GGA CCC TCC TGG TAG ACC GTC GTG TAC CTT CTT GAC CCT 140 Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin CAC OCT CCC ATO CCC CCC TTC CCC TCT GCT TTC CAC CTC.CCA CCC TAC CGC CCC AAGCCC AGA CGA AAG CTC 1601 Ala Ser His Leu Gin Ser Phe Leu Clii Val Ser Tyr CCC TCC CAT' CTG CAG AOC TTC CTC GAG GTG TCG TAC CCC AGO GTA CAC CTC TCG PAC GAC CTC CAC AGC ATO 174 CTT GCC CAG 'CCC TGA GCC AAG CCC.TCC CCA TCC CAT CTA TTT ATC GAA CCC GTC CCC ACT TCT ATT TMA TAT TTA TOT CTA TTT AAC CCT CAT ATT TAA AGA CAd GGA AGA GCA GAA CCC AGC CCC ACG CCT CTC TGT CCT TCC CTO CAT TTC TGA OTT TCA TTC TCC TGC CTG TAG CAG Stut TGA GAA AAA GCT CCT CTC CTC CCA TCC CCT COA CTG GOA CCT AGA TAG GTA MAT ACC MOG TAT TTA TTA CTA TGA CTG CTC CCC ACC CCT CCC TCT GCA ATG CCC ACT CCC ATO AGC CC TGT GAG CCC CTG GTC CTC AOC CTC CCC ACC TCG GAC CCT TOA GAG TAT CAC CTC TCC CAC TABLE VII (cont~d.)

OTG

GCA

GCC

TTG

TCA

GCT

CG

GGA

TCA

GGA

CCC

Ccc

CTG

CCG

CAG

GAC

AC

CAT

GAC AAG CTC ACT TOO ACA CG MAT ACG TGT GAC 'POT TOG OGA TCC ACT TGT MAC

AAA

CTG

AGC

CTC

CTC

GAP,

TOT

GTC

TGA

TCC

CC

AGA

OTT

CTO

TCT

000

ACC

ACT

CTO TTT TCA GCC OCT- GCC TTT CTT TTT TTC TTT TAG ACO GAG CTC CAC TCA

GGA

AAT 'ATT TAA ACA GCA GTG

GAC

CAG

CTT

TG

GCC

CAG

CTC

TGC

AGC

MAG

GTG

CAG

ACA

TTC

ACA GCO GCC TOG GAG GCA ACT TTT 000 GCC TCG GGA OCA GOT GCC OGA GGA ATC ACC CCC CAC

CCT

TOG

ACA

CAC

TG

ATG3

TCA

TTC CCC ATC GCA TCq CCT CCC TOO OCT TOG TTT GAC CTG CCC TGC ACA TTT 0CC TCA GGC CTG Stul CCA GTG

TCC

TOG

TGG

CCC

TCC

CCC

TTO

TGT

CCT

GTC

CTG

ACG

CGA

CAC

CTG

OTG

CCA

CTT

TGA

MAT

ACA

GAG

GAC

AAA

CTG

I~

TAA TMA AGT OTT TOC CTC CA M50-200 base poly (f15-200basepolyA plus 25-30 bases plasmid DNA preceding a PvuII restriction site)-3' 25 The following characteristics of the sequence of Table VII are of note. At the 5' end of the sequence there are shown bases corresponding to those of the poly G cDNA linker. There then occur about five bases (designated as whose sequence could not readily be unambiguously by the Sanger, et al. method due to the preceding multiple G's. The sequence thereafter reveals a series of 12 codons encoding a portion of a putative leader sequence for the polypeptide.

Based on correspondence to the amino terminal sequence of natural isolates of hpCSF described in Example 1, the initial threonine residue of the putative "mature" form of hpG-CSF is indicated by Mature hpG-CSF is thereafter revealed to include 174 residues as indicated. Following the "stop" codon (the OP codon, TGA) are approximately 856 bases of an untranslated 3' sequence and multiple A's of' the poly A "tail". Unique HgiAi, and ADal restriction endonuclease recognition sites, as well as two StuI sites (discussed infra with respect to construction of procaryotic and eucaryotic 20 expression systems) are also designated in Table VII.

Oving to the lack of asparagine residues in the polypeptide, there are no apparent sites for Nglycosylation. The underscored 6 bases near the end of the 3' untranslated sequence represent- a potential S" 25 polyadenylation site.

It is noteworthy that each of two additional cDNA clones identified by the hybridization procedures described above from among a total of 450,000 clones failed to include DNA encoding the entire leader 0 sequence from the transcription initiation site onward. Indeed, all three hpG-CSF clones terminated in the 5' region at exactly the same site, indicating that secondary structure of the mRNA transcribed severely hinders cDNA formation beyond this site. As a practical 26 matter, therefore, cDNA expression screening such as described in Okayama, et al., Mol. and Cell. Biol., 3, 280-289 (1983) and as actually employed to isolate GM- CSF in Wong, et al., Science, 228, 810-814 (1985) could not have readily applied to isolation of hpCSF DNA because such isolation systems ordinarily rely upon the presence of a full length cDNA transcript in the clones assayed.

The above sequence is not readily susceptible for securing direct expression of hpG-CSF in a microbial host. To secure such expression, the hpG-CSF coding region should be provided with an initial ATG codon and the sequence should be inserted in.a transformation vector at a site under control of a suitable promoter/regulator DNA sequence.

Examole In this example, cDNA encoding hpG-CSF as 20 isolated in the previous example was used to screen a genomic clone. A phage lambda human fetal liver genomic library [prepared according to the procedure of Lawn, et al. Cell, 15, 1157-1174 (1978) and obtained from T.

S• Maniatis] was screened using a nick translated prob: consisting of two hpG-CSF cDNA fragments isolated by digestion with HqiAI and StuI (HgiAI to StuI, 649 b.p.; StuI to StuI, 639 A total of approximately 500,000 phage were plated on 12. (15 cm) petri dishes and plaque lifted and hybridized to probe using the Benton/Davison procedure [Benton,.et al., Science, 196, 180 (1977)]. A total of 12 positive clones were observed. Three clones yielding the strongest signals upon autoradiography in a secondary screening were grown in 1 liter cultures and mapped by restriction enzyme digestion and Southern blotting using a radiolabeled 24-mer oligonucleotide (kinased with r- 32 p ATP) 27 5'CTGCACTGTCCAGAGTGCACTGTG3'. The mapping results showed that isolates 1 and 3 were identical and 2 contained 2000 additional bases 5' to the hpG-CSF gene.

Therefore, clone 2 was used for further characterization. DNA from clone 2 was digested with R1 to release an 8500 bp hpG-CSF containing fragment which was subsequently subcloned into pBR322 and further mapped by restriction endonuclease digests, Southern Blotting, M13 subcloning and sequencing. The sequence obtained is as set out in Table VIII.

*ee o *ee **o 9* 0% 0. TABLE VII! CACAGGCTCGGCCGCTTCCAGGCGTCTATCAGCGGCTCAGCCTTTGTTCAGCTGTTCTGTTCAACTCTGGGGCCATTCAGGCCTGGTGGG;CAGC 200 CGGAGGAAGGGAGTTTGAGGGGGGCAAGGCGACGTCAA.AGGAGG ATCAGAGATTCCACAATTTCACAAAACTTTCGCCAGCTTTGTTCCMACCCC 300 CCGATTTGAACUTGAAACTGAGTTATACTATGCCCAGATTCCCGCTCTGG 400(N MetAl&GlyProAlaThr~lnSerProH TATGATAGGGCCCCAGACTGGCCCAAACACCCGAGCCGCACCCGCCCACCAGACCAGGCTGACTGCACCCGAOCC500o -18 etLysLeuMetA TCAACTGT(;GTGGTGCTTGCCCGGAGGGGAGCCCCGCCTGGATGdAGGAGGTGGGTGCAGGGGCTGGGATCCCTT6000 -16 laLeuGInLeuL GGG &ATGGGG&TTAAAGGCACCCAGTGTCCCCGAGAGGGCCTCAGGTGGTAGGGMACAGCATGTCTCCTGAGCCCGCTCTGTCCCCAGCCCTGCAGCTGC 700 49eu rp I ag A 9.~r r I I nG I A ATi cL u I yAo r erL t~ o Se e e u y s e u l~ -103 -1 35102 lArgLyuI leGlnGlyAupc~lyAlaAlaL.uG~nG1uLySLeu GAGGAAGATCCAGGCGAT;CGCACGCTCCAGGAGIAGCTGTATAGGGGGGGTTGGGACCGGGAACAGG 900 GAGAC'CCGCACTCCGAGGCTGAATTAGACGGACGGAGCGGAGATGGAGGAC 1000 TGrGTGGACAOGICTCGGGGTGCGGGATGGGAGTGGACGCATCACATTCAGGAGMGGGCAGCCTTAACGGG(GGT 1100

CAGGGCAGAGAGGAACTACACCTGEGCAGGACATGGAGGGAGGGGA

4 .JGACCAGAGAGCGGGACGGGACGGCCGCCG 1200 36 40 CyDAlaThrTyrLyLeuCyHPoGuGuLeuVaLLeu~ly.Ug1YrLGlylloPrr C ~TATACTCTCTCCATTCACAAGTTCCCCGGACGTCGTGGCCCCGGACCTG 1300 7.S SC *0 71 0 1aProLeuSersgrCygProsorG1,~1aLeuG~nLeu CTCCCCTOAOCAGCTOCCCCAGCCAGGCCJCAC1ETAGTGTCAGA"GGATMGGCTAAG~AGGAGAAGGACCCTG 72 AlaGlyCysLeuserGln 90 100 110

CTCCATAGCGGCCISTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAGGGATCTCCCCCGAGTTGGGTCCCACTGAATCGTGCTG

120 I aAspPh@A1aThrThr I eTrpGlnGIs CCGACTTTGCCACCACCATCTGGCAGCAGGTGAGCCTTGTTGGGCAGGGTGGCCAGGTCGTGCTG3GCATTCTGGGCACCCAGCC;GCGGA 121 IMetGluG CCCTGTCCATGCTGTCAGCCCCCAGCATnCCTCATTTGTMATAACGCCCACTCAGAAGGGCCctACICATCACAGCTCCAAGTGG 1400 1500 1600 1700 1800 0 o. 0. 0.0 TABLE VIII lcant'd.) 130 140 ISO I I L u G l y M e t A P r o A l a L u G I Pk T h r n l a e o l e l s r l e l g r a l G y L u a a i r l ~110 170 174 sI-euGlnSerPheLeuoluValserTyrArgVa1LeuArgiiaLeAlaGInrP TTATCTC&GCCCTTTAGCGGAACGAGACCAGGCCTTGGTCTCCTGATTCGATCCATCCCG 2100 TCTAGCAGTGAOAAAGCTC.I.TCCTCCCATCCCCCATGAGAAAGAAACkGATATCAGCCCCACCG 2200 CTCTGCMGGCCAGGATAGCCGCTGTAGCCCTGCTAGTCCCTGACTAATTAGCCCCTGAAAG 2300 AAATCCCTGTTrAATATTTAAACAGCAGTG4CCCCACGGCTGACCCCCGCCGCATCCAGCCTCTCCT 2400 GGTTAGCC(GCACGGTGCGGTGAGAGCCGGTCAGATGTGGACCTTTTCTAA 2500 TrTlGGGAr-ATGTrGACTCCCGAACTCACCGACGGCCTTTTTGTGCCGACTCCGCCAGGGCGATT 2600 TABLE VIII (cont'd.) GACTCTTTTTAG GGCCAGGCA Gh1TJCCT CGACA T T G C T C G A G G A T G TG G G G A C G C G A G A C T T A GI T T GTTAAGCTCC(TCCCCACCTACCCATACGGCCTCACTGTCACATTGT .A CTOACTTJCAGGATAATAAA TOTIII CCTCCAOTCACOTCCT TrCC TrCCT TrC T G TC A C G T C T G C G G C G G A G G T A G G G G G G C A A G G T CGGG a3A aAG GTCTGGGGAo A OTCCAGGGAGGAG G G A A T C C A T C T T A A C T C G T G A A A T A C G G A C A T CT02 C GACGCT

GOCTAATGCTGGGGACAACGGCA;CGCTGACGATGG

2700 2000 2900 3000 3070 33 A restriction endonuclease map (approximately 3.4 Kb) of genomic DNA containing the hpG-CSF gene is detailed in Figure 1. The restriction endonucleases shown in Figure 1 are: NcoI, N; PstI, P; BamHI, B; Apal, A; XhoI, X; and Kpn, K. The arrows below the map depict the sequencing strategy used to obtain the genomic sequence. The boxed regions are those found in the cDNA clone with the dashed open ended box representing sequence not present in the cDNA clone, but identified by probing mRNA blots. The identification of coding sequences proposed for exon one was carried out by Northern blot analysis. A 24 mer oligonucleotide probe, 5'CAGCAGCTGCAGGGCCATCAGCTT 3 spanning the predicted splice junctures for exons 1 and 2 was hybridized to hpG-CSF mRNA in a Northern blot format. The resulting blot shows an mRNA the same size (-1650 bp) as that seen with an exon 2 oligonucleotide probe. This data combined with the ability to direct expression of hpG-CSF from the pSVGM-Ppol vector (Example 9) using the 20 Met initiation codon depicted in Table VIII, defines the coding sequences contained in exon 1. Exons 2-5 are defined by the coding sequences obtained in the cDNA clone (Ppo2) of the hpG-CSF gene (Table VII).

25 Example 6 This example relates to preparation of a manufactured gene encoding hpG-CSF and including E.coli preference codons.

Briefly stated, the protocol employed was generally as set out in the disclosure of co-owned Alton, et al., PCT Publication No. W083/04053, which is incorporated by reference herein. The genes were designed for initial assembly of component oligonucleotides into multiple duplexes which, in turn, were assembled into three discrete sections. These sections 34 were designed for ready amplification and, upon removal from the amplificati-on system, could be assembled sequentially or through a multiple fragment ligation in a suitable expression vector.

The construction of Sections I, II and II is illustrated in Table IX though XIV. In the construction of Section I, as illustrated in Tables IX and X, oligonucleotides 1-14 were assembled into 7 duplexes (1 and 2 and 9; 3 and 10; 4 and 11; 5 and 12; 6 and 13; and 7 and 14). The 7 duplexes were then ligated to form Section I as shown in Table X. It may also be noted in Table X that Section I includes an upstream Xbal sticky end and a downstream BamHI sticky end useful for ligation to amplification and expression vectors and for ligation to Section II.

*oo 35 TABLE IX EChpG-CSFDNA SECTION I CTAGAAAAAACCAAGGAGGTAATAAA 1 TAATGACTCCATTAGGTCCTLGCTTCTTCT 2 CTGCCCCAAAGCTTCTGCTGAAATGTCTG G 3 AACAGGTTCGTAAAATCCAGGGTGACGGT 4 GCTGCACTGCAAGAAAAACTGTGCGCTA CTTACAAACTGTGCCATCCGGAAGAGC 6 TGGTACTGCTGGGTCATTCTCTTGG 7 CATTATTTATTACCTCCTTGGTTTT~T 8 GCAGAGAAGAAGCAGGACCTAATGGAGT 9 TGTTCCAGACATTTCAGCAGAAAGCTTTGCG CAGCACCGTCACCCTGGATTTTACGAACC 11 TAAGTAGCGCACAGTTTTTCTTGCAGTG 3.2 ACCAGCTCTTCCGGATGGCACAGTTTG 13 GATCCCAAGAGAATGACCCAGCAGT 14 TABLE X EChpG-CSFDNA SECTION

I

CTAGAAAIA

TTTTT

Xba i

CGCAAAGCTT

GCGTTTCGAA

1 20 ACCAkAGGAGG

TGGT'TCCTCC

3 80

TCTGCTGAJAJ

AGACCACTTT

5 140

AAAACTGTGC

TTTTGACACG

12 100

TCTTGG

AGAA CCC TAG 30

TAATAAATAA

ATTATTTATT

90

TGTCTGGAAC

ACAGACCTTG

.40

TGACTCCATT

ACTGAGGTAA

100

AGGTTCGTMA

TCCAAGCATT

A2 50

AGTCCTGCT

TCCAGGACGA

9 4 110 AATCCAGdGT

TTAGGTCCCA

11I 6 170 TCCdGAAGAG

AGGCCTTCTG

.13

TCTTCTCTGC

AGAAGAGACG

120

CACGGTGCTG

CTGCCACGAC

130

CACTGCAAGA

GTGACGTTCT

7 190

TGG;?TCATPC

ACCCAGTAAG

14 150

GCTACTTACA

CGATGAATGT

AACTGTGCCA

TTGACACGGT

CTGGTACTGC

GACCATGACG

DamlI 37-- As illustrated in Tables X-1 and XII, in the' construction of Section II, oligonucleot ides 15-30 were assembled into 8 duplexes (15 and 23; 16 and 24; 17 and- 18 and 26; 19 and 27; 20 and 28; 21 and 29; and 22 and 30). These 8 duplexes were then ligated to forM Section II, as shown in Table XII. As further shown in Table XII, Section* 11 has an upstream BamEI sticky end and a downstream Z'coRI sticky end useful for ligation to an amplification vector and for liga tion to Section I.

Near its downstream end, Section II also includes a downstream SstI site useful in the eventual ligation Sections II and 11I.

TABLE X:7 EChpG-CSFDNA SECTION III GATCCCGTGGGCTCCGCTGTCTTCT TGTCCATCTCAAGCTCTTCAGCTGGC 16 TGGTTGT CTGTCTCA.ACTGCAT7TCTGGT 17 CTGTTCCTGTATCAGGGTCTTCLG 1 *CAAGCTCTGGAAGGTATCTCTCCGGA 19 ACTGGGTCCGACTCTGGACACTCTGCA 25 GCTAGATGTAGCTGACTTTGCTACTAC 2 A TTGGCA.ACAGATGGAAGAGCTCAAAG 22 CACAAGAAGACAGCGGAtCCCACGG 23 ACCAGCCAGCTGAAGAGCTTGAGATG 24 ACAGACCAGAATGCAGTTGAGACAGACA CTTGCAGAAGACCCTGATACAGGA 26 CAGTT"CCGGAGAGATACCTTCCAGAG 27 TACCTCCAGJAGTGTCCAGAGTCGGACC 28 AAATACTLAGTAGCAAAGTCAGCTACATC 29 AATTCTTTGACTCTTCCATCTGTTGCC

C

C

C C

C,

C C C CC C C C C C C C CCC

C

C CC

C

C C

~C

CC.

C

4* C CC CO C C C C C

C**

TAB[JE XII EChpG-CSFDHA SECTION II

GATCCCGTG

GGCAC

.15 20

GGCTCCGCTG

CCGAGGCGAC

30

TCTTCTTGTC

AGAAGAACAG

40.. 16 50 CATCTCAAGC TCTTCAGCTG GCTGGTTGTC GTAGAGTTCG AGAAGTCGAC CGACCAACAG.

24 BauH I 17 80 TGTCTCAACT LTTTCTGGT ACAGAGTTGA CGTAAGACCA 130 140 TCTCTCCGGA ACTGGGTCCG AGAGAGGCCT TGACCCAGGC 90

CTGTTCCTGT

GACAAGGACA

20 150

ACTCTGGACA

TGAGACCTGT

28 18 100

ATCAUGGGTCT

TAGTCCCAGA

26 160

CTCTGCAGCT

GAGACGTCGA

110

TCTGCAAGCT

AGACGTTCGA

170

AGATGTAGCT

TCTACATCGA

19 120

CTGGKUGGTA

GACCTTCCAT

27 21 180

GACTTTGCTA

CTGAAACGAT

29 190

CTACTATTTG

GATGATAAAC

200

GCAACAGATG.

CGTTGTCTAC

22 210

GAAGAGCTCA

CTTCTCGAGT

AAG

TTCTTAA

SstI St IEcoR I 39 Finally, Section III was constructed as shown in Tables XIII and XIV. For this construction, oligonucleotides 31-42 were assembled into 6 duplexes (31 and 37; 32 and 38; 33 arid 39; 34 And 40; 35 and 41; and 36 S and 42). The 6 duplexes were then ligated to form Section III as depicted in Table XIV. As also shown in Table XIV, Section III includes an upstream BamHI sticky end and a downstream EcoRI sticky end- useful for ligating into an amplification vector, and at least in the case of the EcoR'I end, into an expression vector. In addition, Section II has an upstream SstI site useful in the eventual ligation of Sections II and III.

TABLE XIII EChpG-CSFDNA SECTION III .20 GATCCAAAGAGCTCGGTATGGCACCAG 31 CTCTGCAACCGACTCAAGGTGCTATGCCG 32 GCATTCGCTTCTGCATTCCAGCGTCGTGC 33 AGGAGGTGTACTGGTTGCTTCTCATCTG 34 CAATCTTTCCTGGAAGTATCTTACCGTGT TCTGCGTCATCTGGCTCAGCCGTAAT AG 36 **AGAGCTGGTGCCATACCGAGCTCTTTG- 37 ATGCCGGCAT"AGCACCTTGAGTCGGTTGC 38 TCCTGCACGACGCTGGAATGCAGAAGCGA 39 So 0 41 *AATTCTATTACGGCTGAGCCAGATGACG 42 TABLE XIV EChpG-CSFDNA SECTION

III

GATCCAAAG

GTTTC

BamlI.

TTCGCTTCTG

KAGCGAAGAC

31 20 AGCTrGGTAT

TCGAGCCATA

37 SatI 33 80 CATfCi.CAGCG

GTAAGGTCC

.39 30

GGCACCAGCT

CCGTGGTCGA

90

TCGTGCAGGA

AGCACGTCCT

CTGCAACCG0

GACGTTGGCT

100

GGTGTACTGG

CCACATGACC

32 CTC~iGGTGC

GAGTTCCACG

.38 34 110 TTGCfTCTCA

AACGAAGAGT

TATGCCGGC0

ATACGGCCGT

120.

TCTGCAATCT

AGACGTTAGA

130 TTCt-GGAAG

AAGGACCTTC

41 140 150 TATCTTACCG

TGTTCTGCGT

ATAPAATGGC ACAAGACGCA 36 160

CATCTGG;CTC

GTAGACCGAG

ACCGTAATA

G

TCGGCATTAT

CTTAA

42 EcoRlI 41 The XbaI to BamHI fragment formed by Section I is ligated into an Ml3mpll phage vector opened with XbaI and BamHI. The vector is then reopened by digestion with BamHI and EcoRI, followed by ligation with the BamHI to EcoRI fragment formed by Section II. At this stage, Sections I and II have been joined in proper orientation. Next, another Ml3mpll vector is opened by BamHI to EcoRI digestion and then ligated with the BamHI to EcoRI fragment formed by Section III.

The vector containing Sections I and II is digested with XbaI and SstI. Likewise, the vector containing Section III is digested with SstI and EcoRI.

Both of the smaller of the two fragments resulting from each digestion are ligated into a a plasmid pCFM1l56 which is previously opened with XbaI and EcoRI. The product of this reaction is an expression plasmid containing a continuous DNA sequence, as shown in Table XV, encoding the entire hpG-CSF polypeptide with an amino terminal methionine codcn (ATG) for E.coli translation initiation.

0.

00 o 00.0 eeo- 0 0* 0 0 0* 0 00 0 0 0 0 *00 0 0 00 0 000 0 9 00 00 0 0 0 S 0 0 0 0* 00* .00 000 0 000 TABLE XV.

-1 +1 Met Thr Pro Lou Gly Pro Ala Ser+Ser Leu ATA ATG ACT CCA TTA GOT CCT GCT TCT TCT CTG C TAG AA.A AAA CCA AGO AGO TAA CCG CAA AGC TTT CTC CTG AMA TGT Pro Gin Ser.Phe Lou Leu Lys Cys Ala Lou Gin Olu Lys Lou Cys Ala OCA CTG CAA GM AMA CTG TGC GCT Leu Oly Ilia Ser Leu Gly Ile Pro CTG GOT CAT TCT CTT GO ATC CCG Gin Leu Ala Gly Cys Leu Ser Gin CAG CTG GCT GOT TGT CTG TCT CAA Gin Ala Lou Giu Gly Ile Ser Pro CAA GCT CTG GMA GOT ATC TCT CCC 110 Val Ala Asp Pho Ala Thr Thr Ile GTA OCT GAC TTT OCT ACT ACT ATT 130 Leu Gin Pro Thr Gin Gly Ala Met CTG CAA CCG ACT CAA GGT OCT ATG CTG GAA CAG GTT CGT AAA ATC CAG GOT Leu Giu Gin Val Arg Lys Ile Gin Gly GAC GOT OCT Asp Gly Ala Thr Tyr Lys Lou Cys Ilia Pro Glu Giu Leu Val Leu ACT TAC AM C'ro TOC CAT CCG GMA GAG CTG GTA CTG Trp ala Pro Leu Ser. Ser Cys Pro Ser TOG OCT CCG CTO TCT TCT TOT CCA TCT 00 ieu Ills Ser Oly LeuPhe Leu Tyr Gin CTG CAT TCT GOT CTG TTC CTG TAT CAG 100 Glu Leu Gly Pro Thr Lou Asp Thr Lou GAA CTG GOT CCG ACT CTG GAC ACT CTG 120 Trp Gin Gin Met1 Glu Glu leu Gly M4et TOG CAA CAG ATG GMA GAG CTC GGT ATG Gin Ala Lou CMA OCT CTT Oly Leu Leu GOT CTT CTG Gin Leu Asp CAG CTA OAT Ala Pro Ala 140 Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly CCG GCA TTC OCT TCT.OCA TTC CAG COT COT OCA GGiA TABLE XV (cont'd.) 150 160 Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg GGT GTA CTG OTT OCTr TCT CAT CTG CAA TCT TTC CTG GMA GTA TCT TAC COT GTT CTG CGT 17.0 174 His Leu Ala Gin Pro CAT CTG OCT CAG CCG TMA TAG MAT T 44 Although any suitable vector may be employed to express this DNA, -the expression plasmid pCFM1156 -may readily be constructed from a plasmid pCFM836, the construction of which is described in published European Patent Application No. 136,490. pCFM836 is first cut with Ndel and then blunt-ended with Poll such that both existing NdeI sites are destroyed. Next, the vector is digested with Clal and SacII to remove an existing polylinker before ligation to a substitute polylinker as illustrated in Table XVI. This substitute polylinker may be constructed according to the procedure of Alton, et al., supra. Control of expression in the expression pCFM1156 plasmid is by means of a lambda PL promoter, which itself may be under the control of a

CI

857 repressor gene (such as is provided in E.coli strain Kl2AHtrp).

oo...

0 0 0* 0 0 0 0 0e 0 0 TABLE XVI 1 TGTTATTGAGGATAATTGTAGGTGATGTCA TAGCT'IAAACTAAGATC1TCCTCCTTATTGTATACCAATTGCGCAACCTTAAGCCATGGTA I Clal, 12 XbaI, 29 Ndel, 35 luincll, Ilpal, '39 Miul, 47 EcoRll, 53 ligiCl I~pnl, 57 Ncol Stylo 61 GGAAGCTTACTCGAGGATCCGCGGATAAATAAGTAACGATCC .c crTCGAATGAGCTCCTAGGCGCCTATTTATTCATTGCTAGG 63 Ilindlil, 70 Aval Xhol, 75'Bamll Xho2, 79 Sac2, 46 Example 7 This example relates to E. coli expression of an hpG-CSF polypeptide by means of a DNA sequence encoding [Met 1 hpCSF. The sequence employed was partially synthetic and partially cDNA-derived. The synthetic sequence employed E. coli preference codons.

Plasmid Ppo2, containing the hpG-CSF gene shown in Table VII, was digested with HEiAI and StuI providing an approximately 645 base pair fragment including the gene for mature hpCSF (as shown in Table VII) with seven of the leader sequence residue codons at the 5' end and about 100 base pairs of the 3' non-coding region. HgiAI digestion leaves a 4-base sticky end identical to that of PstI, and StuI leaves a blunt end. This allows for ready insertion of the fragment into M13 mp8 (Rf) cut with PstI and with the blunt-endforming restriction enzyme, HincII. Upon amplification in M13, the hpG-CSF DNA was excised by digestion with Apal and BamHI which cut, respectively, at the Apal site ooo spanning the codons for residues +3 to +5 of hpCSF and at a BamHE site "downstream" of the HincII site in the M13 mp8 restriction polylinker. In order to allow for o*o0: E. coli expression of the hpG-CSF polypeptide, a 25 synthetic fragment was prepared as set out in Table XVII below.

TABLE

XVII

30 5' C TAG AAA AAA CCA AGG AGG TAA TAA ATA 3' TTT TTT GGT TCC TCC ATT ATT TAT Xbal -1 +1 Met Thr Pro Leu ATG ACA CCT CTG GGC C TAC TGT GGA GAC -3' Apa I 47 As may be determined from analysis of Table XVII, the linker includes an Apal sticky end, codons specifying the initial three residues of the amino terminal of hpG-CSF ("restoring" the Thr 1 Pro 2 Leu 3 specifying codons deleted upon Apal digestion of the M13 DNA described above and employing codons preferentially expressed in E. coli), a translation initiating ATG, a sequence of 24 base pairs providing a ribosome binding site, and an Xbal sticky end.

The expression vector employed for E. coli expression was that described as pCFM536 in European Patent Application No. 136,490, by Morris, published April 10, 1985. (See also, A.T.C.C. 39934, E. coli JM103 harboring pCFM536). Briefly, plasmid pCFM536 was digested with Xbal and BamHI. The hpG-CSF fragment (AoaI/Bam~I) and linker (Xbal/ApaI) described above were then ligated thereinto to form a plasmid designated p536?po2.

Plasmid p536Po2 was transformed into a phage resistant variant of the E. coli AM7 strain which has previously been transformed with plasmid pMWl (A.T.C.C.

No. 39933) harboring a CI857 gene. Transformation was verified on the basis of the antibiotic (amp) resistance marker gene carried on the pCFM536 progenitor plasmid.

Cultures of cells in LB broth (ampicillin 50 ug lml) were maintained at 28°C. and upon growth of cells in culture to A600 0.5, hpCSF expression was induced by raising the culture temperature to 42*C. for 3 hours.

The final O.D. of the culture was A600 1.2.

The level of expression-of hpG-CSF by the transformed cells was estimated on a SDS-poly acrylamide gel stained with coomassie blue dye to be 3-5% of total cellular protein.

Cells were harvested by centrifugation at 3500 g for 10 minutes in a JS-4.2 rotor. Cells at in water were broken by passing 3 times through a 48 French Pressure Cell at 10,000 p.s.i. The broken cell suspension was centrifuged at 10,000 g for 15 minutes in a JA-20 rotor. The pellet was resuspended in water and solubilized at about 5 mg/ml total protein in 1% lauric acid, 50 mM Tris, pH 8.7. The solubilized pellet material was centrifuged at 15,000 g for 10 minutes and to the supernatant CuSO 4 was added to 20 mM. After 1 hour, this sample was loaded onto a C4 HPLC column for purification according to the procedures of example 1 with adjustmeiits made for volume and concentration.

A second purification procedure was developed to yield larger quantities of hpG-CSF formulated in a nonorganic-containing buffer. This material is suitable for in vivo studies. One hundred and fifty grams of cell paste was resuspended in about 600 -ml of 1 mM DTT and passed 4 times through a Manton Gualin Homogenizer at about 7000 PSI. The broken cell suspension was centrifuged at 10,000 g for 30 minutes and the pellet was resuspended in 400 ml of 1% deoxycholate (DOC), 5 mM EDTA, 5 mM DTT, and 50 mM Tris, pH 9. This suspension was mixed at room temperature for 30 minutes and centrifuged at 10,000 g for 30 minutes. The pellet was resuspended in about 400 ml of water and centrifuged at 25 10,000 g for 30 minutes. The pellet was solubilized in 100 ml of 2% Sarkosyl and 50 mM at pH 8. CuSO 4 was added to 20 uM and the mixture was stirred 16 hours at room temperature, and then centrifuged at 20,000 g for minutes. To the supernatant was added 300 ml acetone. This mixture was put on ice for 20 minutes and then centrifuged at 5000 g for 30 minutes. The pellet was dissolved in 250 ml of 6 M guanidine and 40 mM sodium acetate at pH 4, and put over a 1,200 ml column equilibrated and run in 20 mM sodium acetate at pR 5.4. The hpG-CSF peak (about 400 ml) was pooled and put on a 15 ml CM-cellulose column equilibrated in 20 mM 49 sodium acetate at pE 5.4. After loading, the column was washed with 60 ml of .20 mM sodium acetate at pH 5.4 and with 25 mM sodium chloride, and then the column was eluted with 200 ml of 20 mM sodium acetate at pH 5.4 and with 37 mM sodium chloride. 150 ml of this eluent was concentrated to 10 ml and applied to a.300 ml column equilibrated and run in 20 mM sodium acetate and 100 mM sodium chloride at pH 5.4. The peak fractions comprising 35 ml were pooled and filter sterilized. The final concentration of hpG-CSF was 1.5 mg/ml, is greater than 95% pure as determined by analysis on a gel, and contained less than 0.5 ng of pyrogen per 0.5 mg of hpG-CSF. The pyrogen'level was determined using a Limulus Amebocyte Lysate (LAL) test kit A.

Bioproducts, Walkersville, Maryland).

Example 8 This example relates to the use of recombinant 20 methods to generate analogs of hpG-CSF wherein cysteine S.residues present at positions 17, 36, 42, 64 and 74 were individually replaced by a suitable amino acid residue.

:Site directed mutagenesis procedures according 25 to Souza, et al., published PCT Application No.

W085/00817, published February 28, 1985, were carried out on [Met 1 encoding DNA of plasmid p536Ppo2, described infra, using synthetic oligonucleotides ranging in size from 20 to 23 bases as set out in Table XVIII 30 below. Oligonucleotide No. 1 allowed for formation of a gene encoding [Serl7]hpG-CSF; oligonucleotide No. 2 allowed for formation of [Ser 3 6 ]hpG-CSF, and so on.

50 T&ABLE XVIII Oliconucleotide Secuence 1. 5'-CTG CTC AAG TCC TTA GAG CAA GT-34 2. 5'-GAG AAG CTG TCT GCC ACC TACA-3- 3. 5 1-TAC A.AG CTG. TCC CAC CCC GAG-3- 4. 5'-TGA GCA GCT CCC CCA GCC AC-38 5'-CTG GCA GGC TCC TTG AGC CA6A-3' The Cys to Ser site directed mutagenesis restrictions wer .e carried out using 2413 mplO containing an XbaI-BarLRI hpG-CSF fragment isolated from p536Ppo2 as a template. DNA from each MJ.3mplO clone containing a Cys-Ser substitution was treated with XbaI and Bam.I The resulting fragment was cloned into expression vector ~PCFM746 and express ion products were isolated as in Example 7.

The plasmid pCFM746 may be constructed by cleaving a plasmid pCFM736 (the construction oil whi-ch f.rom deposited and publically available materials Is described in Morris, published PCT ApplicatIon No.

W085/00829, publi shed February 28, 1985) with Clal and *25 BamHI to remove an existing polylinker and by substituting the following polylinker.

TABLE XIX 51.Clal

CGATTTGATTCTAAATT'CGTTAACGGTACCATGGA.A

3 TAAACTAAGATCTTAAGCAAT"TGCCATGGTACCTT

GCT'TACTCGAGGATCCGCGGATAAATAACTAAC

3 1

CGAATGACCTCCTAGGCGCCTATTTATTCATT"IGCTAG

Sau3a 51 In a purification procedure for Cys to Ser analogs according to the present invention, about 10-15 g of cell paste was resuspended in 40 ml of 1 mM DTT and passed 3 times through a French Pressure Cell at 10,000 psi. The broken cell suspension was centrifuged at 1,000 g for 30 minutes. The pellet was resuspended in 1% DOC, 5- mM EDTA, 5 mM DTT, 50 mM Tris, pH 9 and allowed to mix 30 minutes at room temperature. The mixture was centrifuged at 10,000 g for 30 minutes, resuspended in 40 ml H 2 0, and recentrifuged as 10,000 g for 30 minutes. The pellet was dissolved in 10 ml of 2% Sarkosyl, 50 mM DTT, 50 mM Tris, pH 8. After mixing for 1 hour, the mixture was clarified by centrifugation at 20,000 g for 30 minutes, and then applied to a 300 ml column equilibrated and run in 1% Sarkosyl, 50 mM Tris, pH 8. Fractions containing the analog were pooled and allowed to air oxidize by standing with exposure to air for at least one day. Final concentrations ranged "i 20 from 0.5 5 mg/ml.

Example 9 In this example, a mammalian cell expression system was devised to ascertain whether an active polypeptide product of hpG-CSF DNA could be expressed in and :*":secreted by mammalian cells (COS-1, A.T.C.C. CRL- 1650). This system was designed to provide for secretion of a polypeptide analog of hpGCSF via expression S: 30 and secretory processing of a partially synthetic, partially cDNA-derived construction encoding [Ala 1 hpG-CSF preceded by a leader polypeptide having the sequence of residues attributed to human GM-CSF in Wong, et al., Science, 228, 810-15. (1985) and Lee, et al., Proc.

Natl. Acad. Sci. 82, 4360-4364 (1985).

52 The expression vector employed for preliminary studies of expression of polypeptide products of the invention was a "shuttle" vector incorporating both pBR322 and SV40 DNA which had been designed to allow for autonomous replication in both E. coli and ma-alian cells, with mammalian cell expression of inserted exogenous DNA under control of a viral promoter/regulator DNA sequence. This vector, designated pSVDM-19, harbored in E, coli EB10o, was deposited August 23, 1985, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, and received the accession No. A.T.C.C. 53241.

The specific manipulations involved in the expression vector construction were as follows. A leader-encoding DNA sequence was synthesized as set out in Table XX below.

20 TABL.E XX -17 HindlIl Met Trp GCT TCC AAC ACC ATG TGG 3' AGG TTG TGG TAC ACC Gln Ser Leu Leu Leu Leu Gly Thr Val CTG CAG AGC C'rG CTG CTC TTG GGC ACT GTG GAC GTC TCG GAC GAC GAG AAC CCG TGA CAC +1 Ala Cys Ser Ile Ser Ala Pro Leu GCC TGC AGC ATC TCT GCA CCC CTG GGC G -3' CGG ACG TCG TAG AGA CGT GGG GAC Apa I 53 As indicated in.Table XX, the sequence includes HindIII and Apal sticky ends and codons for the 17 amino acid residues attributed to the "leader" of human GM-CSF. There follow codons specifying an alanine residue, a proline residue and a leucine residue. The proline and leucine residues duplicate the amino acids present at positions +2 and +3 of hpG-CSF, while the alanine residue is duplicative of the initial amino terminal residue of GM-CSF rather than hpG-CSF.

Replacement of threonine by alanine was designed to be facilitative of proper host cell "processing off" of the GM-CSF leader by cellular mechanisms ordinarily involved in GM-CSF secretory processing.

Plasmid pSVDM-19 was digested with KpnI and the site was blunt ended with Klenow enzyme. Thereafter the DNA was cut with HindIII. The resulting large fragment was combined and ligated with the HindIII/PvuII fragment shown in Table VII (isolated from plasmid Ppo2 as the second largest fragment resulting from HindIII S" digestion and partial digestion with PvuII) to form S" plasmid pSV-Ppol. The manufactured GM-CSF leader sequence fragment of Table VIII was then ligated into pSV-Ppol (following its cleavage with HindIII and Apal) "25 to yield plasmid pSVGM-Ppol.

Calcium phosphate precipitates (l-5ug) of plasmid pSVGM-Ppol DNA was transformed into duplicate mm plates of COS-1 cells essentially as described in Wigler, et al., Cell, 14, 725-731 (1978). As a control, plasmid pSVDM-19 was also transformed into COS-1 cells. Tissue culture supernatants were harvested days post-transfection and assayed for hpG-CSF activity. Yields of [Alal]hpG-CSF from the culture supernatant were on the.order of 1 to 2.5 ug/ml.

Following successful expression of the [Alal]hpG-CSF product encoded plasmid pSVGM-Ppol in 54 COS-1 cells, another vector was constructed which included the human GM-CSF leader sequence but had a codon for a threonine residue (naturally occurring at position 1 of hpG-CSF) replacing the codon for alanine at that position. Briefly, an oligonucleotide was synthesized (5'CAGCATCTCTACACCTCTGGG) for site-directed mutagenesis (SDM). The HindIII to BamHI hpG-CSF fragment in pSVGM-Ppol was ligated into Ml3mpl0 for the SDM. The newly synthesized hpG-CSF gene containing a Thr codon in position one was isolated by cleavage with HindIII and EcoRI. The fragment was then cloned into pSVDM-19 prepared by cleavage with the same two restriction endonucleases. The resulting vector pSVGM-Ppo(Thr) was transformed into COS cells and the yields of hpG-CSF measured in the culture supernates ranged from 1 to ug/m1.

Finally, the genomic sequence whose isolation is described in Example 5 was employed to form an expression vector for mammalian cell expression of 20 hpG-CSF. More specifically, pSVDM-19 was digested with KDnI and HindIII and the large fragment used in a fourway ligation with a synthetic linker with HindIII and Ncol sticky ends, as shown in Table XXI. An Ncol-BamHI fragment containing exon 1 isolated from pBR322 (8500 i 25 hpG-CSF), a genomic subclone, and a BamHI-KpnI fragment containing exons 2-5 isolated from the plasmid pBR322 (8500 hpG-CSF genomic subclone). The resulting mammalian expression vector, pSV/ghG-CSF produced 1 to ug/ml of hpG-CSF from transformed COS cells.

TABLE XXI HindIII Ncol 55 Example This example relates to physical and biological properties or recombinant polypeptide products of the invention.

1. Molecular Weight Recombinant hpG-CSF products of E. coli expression as in Example 7 had an apparent molecular weight of 18.8 kD when determined in reducing SDS-PAGE (as would be predicted from the deduced amino acid analysis of Table VII whereas natural isolates purified as described in Example 1 had an apparent molecular weight of 19.6 kD. The presence of N-glycans associated with the natural isolates could effectively be ruled out on the basis of the lack of asparagine residues in the primary sequence of hpG-CSF in Table VII and therefore a procedure was devised to determine if O-glycans were responsible for molecular weight differences between 20 natural isolates and the non-glycosylated recombinant .products. Approximately 5 ug of the natural isolate material was treated with neuraminidase (Calbiochem, LaJolla, California), a 0.5 ug sample was removed, and the remaining material was incubated with 4 mJ O- Glycanase (endo-x-n-acetylgalactoseaminidase, Genzyme, Boston, Massachusetts) at 37 0 C. Aliquots were removed after 1/2, 2 and 4 hours of incubation. These samples were subjected to SDS-PAGE side by side with the E. coli derived recombinant material. After neuraminidase treatment, the apparent molecular weight of the isolate shifted from 19.6 kD to 19.2 kD, suggestive of removal of a sailic acid residue. After 2 hours of treatment with O-glycanase, the molecular weight shifted to 18.8 kD identical to the apparent molecular weight of the E. coli derived material. The sensitivity of the carbohydrate structure to neuraminidase and O-glycanase 56 suggests the following structure for the carbohydra-te component: N-acetylneuraminic acid-a(2-6)(galactose s N-acetylgalactoseamine-R, wherein R is serine or threonine.

2. 3 H-Thymidine Uptake Proliferation induction of human bone marrow cells was assayed on the basis of increased incorporation of 3 H-thymidine. Human bone marrow from healthy donors was subjected to a density cut with Ficoll-Hypaque (1.077g/ml, Pharmacia) and low density cells were suspended in Iscove's medium (GIBCO) containing 10% fetal bovine serum and glutamine pen-strep.

Subsequently, 2xl0 4 human bone marrow cells were incubated with either control medium or the recombinant E.

coli material of Example 7 in 96 flat bottom well plates at 37 0 C. in 5% CO 2 in air for 2 days. The samples were assayed in duplicate and the concentration varied over a 10,000 fold range. Cultures were then pulsed for 4 20 hours with 0.5 v Ci/well of 3 H-Thymidine (New England Nuclear, Boston, Massachusetts). 3 H-Thymidine uptake was measured as described in Ventua, et al., Blood, 61, 781 (1983). In this assay human hpG-CSF isolates can induce 3 H-Thymidine incorporation into human bone marrow 25 cells at levels approximately 4-10 times higher than control supernatants. The E. coli-derived hpG-CSF material of Example 6 had similar properties.

A second human bone marrow cell proliferation study was carried out using culture medium of transfected COS-1 cells as prepared in Example 9 and yielded similar results, indicating that encoded polypeptide products were indeed secreted into culture medium as active materials.

57 3. WEEI-3B D Differentiation Induction Capacity of recombinant, E. coli-derived materials to induce differentiation of the murine myelomonocytic leukemic cell line WEHI-3B D was assayed in semi-solid agar medium as described in Metcalf, Int. J.

Cancer, 25, 225 (1980). The recombinant hpG-CSF product and media controls were incubated with -60 WEHI-3B D' cells/well at 370C. in 5% CO 2 in air for 7 days. The samples were incubated in 24 flat bottom well plates and the concentration varied over a 2000-fold range.

Colonies were classified as undifferentiated, partially differentiated or wholly differentiated and colony cell counts were counted microscopically. The E. coli recombinant material was found to induce differentiation.

4. CFU-GM, BFU-E and CFU-GEMM Assays Natural isolates of pluripotent human G-CSF (hpG-CSF) and the recombinant pluripotent human G-CSF (rhpG-CSF) were found to cause human bone marrow cells to proliferate and differentiate. These activities were Smeasured in CFU-GM [Broxmeyer, et al., Exp.Hematol., 87, (1971)] BFU-E and CFU-GEMM assays [Lu, et al., Blood, 61, 250 (1983)] using low density, non-adherent 25 bone marrow cells from healthy human volunteers. A comparison of CFU-GM, BFU-E and CFU-GEmm biological activities using either 500 units of hpG-CSF or rhpG-CSF are shown in Table XXII below.

All the colony assays were performed with low 30 density non-adherent bone marrow cells. Human bone marrow cells were subject to a density cut with Ficoll- Bypaque (density, 1.077 g/cm3; Pharmacia). The low density cells were then resuspended in Iscove's modified Dulbecco's medium containing fetal calf serum and placed for adherence on Falcon tissue culture dishes (No. 3003, Becton Dickenson, Cockeysville, MD.) for 1-1/2 hours at 370C.

58 TABLE XXII CFU-GM BFU-E CFU-GEMM Medium 0:0 26:1 0:0 natural hpG-CSF 83:5.4 83=6.7 rhpG-CSF 87:5 81:0.1 6:2 Medium control consisted of Iscove's modified Dulbecco medium plus 10% FCS, 0.2 mM hemin and 1 unit of recombinant erythropoietin.

For the CFU-GM assay target cells were plated at 1 x 105 in 1 ml of 0.3% agar culture medium that included supplemented McCoy's SA medium and 10% heat inactivated fetal calf serum. Cultures were scored for colonies (greater than 40 cells per aggregate) and morphology assessed on day 7 of culture. The number of colonies is shown as the mean iSEM as determined from Squadruplicate plates.

For the BFU-E and CFU-GEMM assays, cells (1 x 105) were added to a 1 ml mixture of Iscove's modi- 25 fied Dulbecco medium (Gibco), 0.81 methylcellulose, 301 se* fetal calf serum 0.05 nM 2-mercaptoethanol, 0.2 mM hemin and 1 unit of recombinant erythropoietin. Dishes were incubated in a humidified atmosphere of 51 CO 2 and 02. Low oxygen tension was obtained using an oxyreducer from Reming Bioinstruments (Syracuse, Colonies were scored after 14 days of incubation. The number of colonies is shown as the mean tSEM, as determined from duplicate plates.

Colonies foxmed in the CFU-GM assay were all found to be chloracetate esterase positive and nonspecific esterase (alpha-naphthyl acetate esterase) 59 negative, consistent with the colonies being granuloeyte in type. Both natural hpG-CSF and rhpG-CSF were found to have a specific activity of a approximately 1 x 108 U/mg pure protein, when assayed by serial dilution in a CFU-GM assay. The BFU-E and CFU-GEMM data in Table XXII are representative of three separate experiments and similar to the data reported previously for natural hpG-CSF. It is important to note that the rhpG-CSF is extremely pure and free of other potential mammalian growth factors by virtue of its production in E.coli.

Thus rhpG-CSF is capable of supporting mixed colony formation (CFU-GEMM) and BFU-E when added in the presence of recombinant erythropoietin.

5. Cell Binding Assays It was previously reported that WEHI-3B(D cells and human leukemic cells from newly diagnosed leukemias will bind 125 I-labeled murine G-CSF and that this binding can be complete for by addition of 20 unlabeled G-CSF or human CSF-3. The ability of natural hpG-CSF and rhpG-CSF to compete for binding of 125 I-hpG-CSF to human and murine leukemic cells was tested. Highly purified natural hpG-CSF pure; lug) was iodinated [Tejedor, et al., Anal.Biochem., 127, 143 (1982)] was separated from reactants by gel filtration and ion exchange chromatography. The specific activity of the natural 125 -hpG-CSF was approximately uCi/pg protein. Murine WEHI-3B.(D and two human peripheral blood myeloid leukemic cell preparations (ANLL, one classified as M4, the other as M5B) were tested for their ability to bind 125 I-hpG-CSF.

O The murine and freshly obtained human peripheral blood myeloid leukemic cells were washed three times with PBS/1% BSA. WEHI-3B(D cells (5 x 106) or fr-esh leukemic cells (3 x 106) were incubated in duplicate in PBS/1% BSA (100 ul) in the absence or presence 60 of various concentrations (volume: 10 ul) of unlabeled hpG-CSF, rhpG-CSF or GM-CSF and in the presence of 125 I-hpG-CSF (approx. 100,000 cpm or 1 ng) at 0°C. for min. (total volume: 120 ul). Cells were then resuspended and layered over 200 ul ice cold FCS in a 350 ul plastic centrifuge tube and centrifuged (1000 g; 1 min.). The pellet was collected by cutting off the end of the tube and pellet and supernatant counted separately in a gamma counter (Packard).

Specific binding (cpm) was determined as total binding in the absence of a competitor (mean of duplicates) minus binding (cpm) in the presence of 100-fold excess of unlabeled hpG-CSF (non-specific binding). The .non-specific binding was maximally 2503 cpm for WEHI-3B(D cells, 1072 cpm for ANLL (M4) cells and 1125 cpm for ANLL (MSB) cells. Experiments one and two were run.on separate days using the same preparation of 125 I-hpG-CSF and display internal consistency in the percent inhibition noted for 2000 units of hpG-CSF.

20 Data obtained are reported in Table XXIII below.

TABLE XXIII Competitor Expel1 none natural jipG-CSFt (U/mi).

CPM I Inhib.- ANLL (M4) CPM I Inhib.

ANLL (M59) cpm Inhib.

0 6,608 1,218 122 10,0000 2,000 200 100000 2,000 200 685 1,r6 92 2o031 .0 1,185 2,330 97 -376 rhpG-CSF: 100 02 202 Exp. 2 none natural hpG-CSF: 0 2,910 2,000 628 GM-CSF: 2,000 3310 3,311 0 62 As shown in Table XXIII, 1 25 I-hpG-CSF demonstrated binding to the WEHI-3B(D leukemic cells. The binding was inhibited in a dose dependent manner by unlabeled natural hpG-CSF or rhpG-CSF, but not by GM-CSF. In addition, binding of natural hpG-CSF to human myelomonocytic leukemic cells (ANLL, M4) was observed. The binding to these cells is paralleled in response to natural hpG-CSF in liquid cultures by differentiation into mature macrophages as judged by morphology. -The absence of binding of natural 125 I-hpG-CSF to monocytic leukemic cells from another patient (ANLL, M5B) suggests that certain leukemias may differentially express or lack receptors for hpG-CSF.

The ability of rhpG-CSF to compete for the binding of natural 125 I-hpG-CSF, similar to natural hpG-CSF, suggests that the receptors recognize both forms equally well.

These studies demonstrating the binding of natural 12 5 I-labeled hpG-CSF to leukemic cells are 20 paralleled in culture by the ability of natural hpG-CSF to induce granulocytic and monocytic differentiation of light density bond marrow cells obtained from one patient with an acute promyelocytic leukemia (M3) and a second patient with an acute myeloblastic leukemia 25 Cells from each patient were cultured for four days in medium alone or in the presence of 1 x 105 units of rhpG-CSF. Cells from the M3 control cultures incubated in medium alone were still promyelocyte in type; while cells cultured in the presence of rhpG-CSF showed 30 mature cells of the myeloid type including a metamyelocyte, giant band form and segmented meutrophilis and monocyte. The actual differentials for this patient, on 100 cells evaluated for the control, 100% promyelocytes, and for the rhpG-CSF treated cells, 22% blasts plus promyelocytes, 7% myelocytes, 35% metamyelocytes, band forms plus segmented neutrophils, 14% monocytes and 63 2% macrophages. Of note is the fact that one of the polymorphonuclear granulocytes still contained a prominent auer rod, suggesting that at least this cell -represented a differentiated cell belonging to the leukemic clone. Cells from the second patient with a myeloblastic leukemia (M2) were also cultured for four days in the presence of absence of rhpG-CSF. Visual analysis of M2 cells cultured in medium alone revealed large "blast-like" cells, some of which had nucleoli. Some of the M2 cells, when treated with rhpG-CSF, differentiated to mature segmented neutrophils displaying residual auer rods in the center neutrophil suggesting differentiation occurring in a cell belonging to the leukemic clone.

The actual differentiation of 100 cells evaluated morphologically revealed that control cells consisted of 100% blasts. The rhpG-CSF treated cells consisted of 43% blasts, 1% myelocytes, 15% metamyelocytes, 28% band forms plus segmented neutrophils, 2% promonocytes and 11% monocytes. The leukemic cells were also examined 20 for differentiation at four other concentrations of rhpG-CSF (5 x 103, 1 x 10 4 2.5 x 104 and 5 x 104 U/m, data not shown). Even at the lowest concentration of rhpG-CSF tested (5 x 103 U/ml), there was significant differentiation (cells differentiated beyond myelocytes) of the M3 and M2 leukemic cells.

6. Irrnunoassay To prepare polyclonal antibodies for immunoassay use the antigen employed was pluripotent G-CSF purified from the human bladder carcinoma cell line 5637 (1A6) as prepared in Example 1 This material was judged to be 85% pure based on silver nitrate staining of polyacrylamide gels. Six week-old Balb/C mice were immunized with multiple-site subcutaneous injections of antigen. The antigen was resuspended in PBS and emulsified with equal volumes of Freund's complete adjuvant.

64 The dose was 5 to 7 ug of antigen per mouse per injection. A booster immunization was administered 18 days later with the same amount of antigen emulsified with an equal volume of Freund's incomplete adjuvant. 4 days later mouse serum was taken to test for the antibody specific to human pluripotent G-CSF.

Dynatech Immulon II Removawell strips in holders (Dynateck Lab., Inc., Alexandria, Virginia) were coated with hpG-CSF 5 ug/ml in 50mM carbonate-bicarbonate buffer, pH 9.2. Wells were coated with 0.25 ug in a volume of 50 ul. Antigen coated plates were incubated 2 hours at room temperature and overnight at 4 0 C. The solution was decanted and the plates were incubated 30 minutes with PBS containing 5% BSA to block the reactive surface. This solution was decanted and the diluted preimmune or test sera were added to the wells and incubated for 2 hours at room temperature.

Sera were diluted with PBS, pH 7.0 containing 1% BSA.

"The serum solution was decanted and plates were washed three times with Wash Solution (KPL, Gaithersburg, Maryland). Approximately 200,000 cpm of iodinated rabbit anti-mouse IgG (NEN, Boston, Massachusetts) in ul PBS, pH 7.0 containing 1% BSA was added to each well. After incubating 1-1/2 hours a- room temperature, 25 the solution was decanted and plates were washed 5 times with Wash Solution. Wells were removed from holder and counted in a Beckman 5500 gamma counter. High-titered mouse sera showed greater than 12-fold higher reactivity than the corresponding preimmune sera at a dilution of S 30 1:100.

The immunological properties of E. coliderived hpG-CSF were determined by reactivity to hightitered mouse serum specific to mammalian-cell derived hpG-CSF. 0.25 ug of 90% pure E. coli-derived protein was coated to Immulon II Removawells in a volume of ul and mouse serum was assayed as described above.

65 High-titered mouse sera showed a 24-fold higher reactivity to the E. coli-derived material than did the corresponding preimmune sera at a dilution of 1:100.

7. Serine Analog Bioassays [Serl7]hpG-CSF, [Ser36]hpG-CSF, [Ser 42 ]hpG-CSF, [Ser 64 ]hpG-CSF, and [Ser 7 4 ]hpG-CSF products prepared according to Example 9 were assay for hpG-CSF activity in the 3H-thymidine uptake, CFU-GM, and WEHI3B D assays. In each assay, the [Serl 7 analog had activity comparable to that of recombinant molecules having the native structure. The remaining analogs had on the order of 100-fold lesser activity in the 3Hthymidine uptake assay, 250-fold lesser activity in the CFU-GM assay, and 500-fold lesser activity in the WEHI-3B D assay. This data is supportive of the proposition that cysteines at positions 36, 42, 64 and 74 may "be needed for full biological activity.

8. In vivo Bioassay Alzet* osmotic pumps (Alzet Corp., Palo Alto, CA; Model 2001) were connected to indwelling right jugular vein catheters and implanted subcutaneously in 25 seven male Syrian golden hamster. Four of the pumps contained a buffer (20 mM sodium acetate (pH 5.4) and 37 mM sodium chloride] and 1.5 mg/ml E.coli-derived 'ss hpG-CSF while 3 contained buffer alone. The claimed pumping rate for the osmotic pumps was 1 microliter/hr.

30 for up-to seven days. At the third day after implantation of the pumps, the mean granulocyte count of the four treated hamsters was six-fold higher than that of the three (buffer) controls and the increased granulocyte count was reflected in a four-fold increase in total lymphocytes. Erythrocyte count was unchanged by treatment. These results indicate that the recombinant 66 material produces a specific enhancement of production and/or release of granulocytes in a mammal.

In addition to naturally-occurring allelic forms of hpG-CSF, the present invention also embraces other hpG-CSF products such as polypeptide analogs of -hpG-CSF and fragments of hpG-CSF. Following the procedures of the above-noted published application by Alton, et al. (WO/83/04053) one may readily design and manufacture genes coding for microbial expression of polypeptides having primary conformations which differ from that herein specified for in terms of the identity or location of one or more residues substitutions, terminal and intermediate additions and deletions).

Alternately, modifications of cDNA and genomic genes may be readily accomplished by well-known site-directed mutagenesis techniques and employed to generate analogs and derivatives of. Such products would share at least one of the biological properties of hpG-CSF but may differ in others. As examples, projected products of 20 the invention include those which are foreshortened by deletions; or those which are more stable to hydrolysis (and, therefore, may have more pronounced or longer lasting effects than naturally-occurring); or which have been altered to delete one or more a potential sites for o-glycosylation (which may result in higher activities for yeast-produced products); or which have one or more cysteine residues deleted or replaced by, alanine or serine residues and are potentially S* more easily isolated in active form from micrbial systems; or which have one or more tyrosine residues replaced by phenylalanine and may bind more or less "readily to hpG-CSF receptors on target cells. Also comprehended are polypeptide fragments duplicating only a part of the continuous amino acid sequence or secondary conformations within hpG-CSF, which fragments may possess one activity of receptor binding) and 67 not others colony growth stimulating activity).

It is noteworthy that activity is not necessary for any one or more of the products of the invention to have therapeutic utility [see, Weiland, et al., Blut, 44, 173-175 (1982)] or utility in other contexts, such as in assays of hpG-CSF antagonism. Competitive antagonists may be quite useful in, for example, cases of overproduction of hpG-CSF.

According to another aspect of the present invention, the DNA sequence described herein which encodes hpG-CSF polypeptides is valuable for the information which it provides concerning the amino acid sequence of the mammalian protein which has heretofore been unavailable despite analytical processing of isolates of naturally-occurring products. The DNA sequences are also conspicuously valuable as products useful in effecting the large scale microbial synthesis of hpG-CSF by a variety of recombinant techniques. Put another way, DNA sequences provided by the invention are useful in generating new and useful viral and circular plasmid DNA vectors, new and useful transformed and o transfected microbial procaryotic and eucaryotic host cells (including bacterial and yeast cells and mammalian cells grown in culture), and new and useful methods for cultured growth of such microbial host cells capable of expression of hpG-CSF and its related products. DNA sequences of the invention are also conspicuously suitable materials for use as labelled probes in isolating hpG-CSF and related protein encoding human genomic DNA 30 as well as cDNA and genomic DNA sequences of other mammalian species. DNA sequences may also be useful in various alternative methods of protein synthesis in insect cells) or in genetic therapy in humans and other mammals. DNA sequences of the invention are expected to be useful in developing transgenic mammalian species which may serve as eucaryotic "hosts" for pro- 68 duction of hpG-CSF and hpG-CSF products in quantity.

See, generally, Palmiter, et al., Science, 222(4625), 809-814 (1983).

Of applicability to hpG-CSF fragments and polypeptide analogs of the invention are reports of the immunological activity of synthetic peptides which substantially duplicate the amino acid sequence extant in naturally-occurring proteins, glycoproteins and nucleoproteins. More specifically, relatively low molecular weight polypeptides have been shown to participate in immune reactions which are similar in duration and extent to the immune reactions of physiologically significant proteins such as viral antigens, polypeptide hormones, and the like. Included among the immune reactions of such polypeptides is the provocation of the formation of specific antibodies in immunologically active animals. See, Lerner, et al., Cell, 23, 309-310 (1981); Ross, et al., Nature, 294, 654-656 (1981); Walter, et al., Proc. Natl. Acad. Sci. (USA), 20 77, 5197-5200 (1980); Lerner, et al., Proc. Natl. Acad.

Sci. (USA), 78, 3403-3407 (1981); Walter, et al., Proc.

Natl. Acad. Sci. (USA), 78, 4882-4886 (1981); Wong, et al., Proc. Natl. Acad. Sci. (USA), 78, 7412-7416 (1981); Green, et al., Cell, 28, 477-487 (1982); Nigg, et al., Proc. Natl. Acad. Sci. (USA), 79, 5322-5326 (1982); Baron, et al., Cell, 28, 395-404 (1982); Dreesman, et al., Nature 295, 185-160 (1982); and Lerner, Scientific American, 248, No. 2, 66-74 (1983). See, also, Kaiser, et al., Science, 223, 249-255 (1984) o 30 relating to biological and immunological activities of synthetic peptides which approximately share secondary structures of peptide hormones but may not share their primary structural conformation.

While the present invention has been described in terms of preferred embodiments, it is understood that variations and modifications will occur to those skilled 69 in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

Claims (40)

1. An isolated polypeptide consisting only of part or all of the amino acid sequence 1- 174 set forth in Table VII which: has one or more of the biological properties typical of naturally- occurring human pluripotent granulocyte colony-stimulating factor (hpG- CSF) of the sequence set forth in Table VII; is a non-naturally occurring polypeptide; and is the product of procaryotic or eucaryotic expression of an exogenous DNA sequence.

2. A polypeptide according to claim 1 wherein the exogenous DNA sequence is a cDNA sequence.

3. A polypeptide according to claim 1 wherein the exogenous DNA sequence is carried on an autonomously replicating DNA plasmid or viral vector.

4. A polypeptide according to claim 1 further characterized by being covalently associated with a detectable label substance. A polypeptide according to claim 4 wherein said detectable label is a radiolabel.

6. A DNA sequence which codes upon expression in a procaryotic or eucaryotic host cell for a polypeptide product having at least a part of the primary structure and one or more of the biological properties of naturally-occurring pluripotent granulocyte 20 colony-stimulating factor, said DNA sequence being selected from among: the DNA sequence set out in Table VII or the complementary stands thereof; DNA sequences which hybridize to the DNA sequences defined in or fragments thereof; and 25 DNA sequences which, but for the degeneracy of the genetic code, would hybridize to the DNA sequences defined in or and which sequences code for a polypeptide having the same amino acid sequence.

7. A procaryotic or eucaryotic host cell transformed or transfected with a DNA sequence according to claim 6 in a manner allowing the host cell to express said polypeptide product. 71

8. A host cell according to claim 7 wherein the host is E. coli.

9. A host cell according to claim 7 wherein the host cell is a mammalian cell. A cDNA sequence according to claim 6.

11. A genomic DNA sequence according to claim 6.

12. A DNA sequence according to claim 6 and including one or more codons preferred for expression in E. coli cells.

13. A DNA sequence according to claim 6 and coding for expression of human pluripotent granulocyte colony-stimulating factor.

14. A DNA sequence according to claim 13 and including one or more codons preferred for expression in yeast cells. A DNA sequence according to claim 10 or claim 11 coding for expression of human pluripotent granulocyte colony-stimulating factor.

16. A DNA sequence according to claim 6 covalently associated with a detectable label substance.

17. A DNA sequence according to claim 16 wherein the detectable label is a radiolabel.

18. A single-stranded DNA sequence according to claim 16.

19. A DNA sequence coding for (Ala') hpG-CSF. A biologically functional plasmid or viral DNA vector including a DNA sequence according to claim 6.

21. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to claim "22. A process for the production of a polypeptide having part or all of the primary structure and one or more of the biological properties of naturally occurring pluripotent 25 granulocyte colony-stimulating factor, which process is characterized by culturing under suitable nutrient conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA sequence according to claim 6 in a manner allowing the host S: cell to express said polypeptide, and isolating desired polypeptide products of the expression of DNA sequence.

23. A process for the production of a polypeptide having the primary structure of human pluripotent granulocyte colony-stimulating factor, which process is characterized by culturing under suitable nutrient conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA sequence set forth in Table VII in a manner allowing the host cells to express said polypeptide, and isolating desired polypeptide products of the expression of the DNA sequence.

24. A pharmaceutical composition comprising an effective amount of a polypeptide according to claim 1 and/or produced by the process of claim 22 or claim 23 and a pharmaceutically acceptable diluent, adjuvant or carrier. A pharmaceutical composition according to claim 24 further characterized by being free of association with any human protein.

26. Use of a polypeptide according to claim 1 for the manufacture of a medicament for providing hematopoietic therapy to a mammal.

27. Use of a polypeptide according to claim 1 for the manufacture of a medicament for arresting proliferation of leukemic cells.

28. A DNA sequence coding for a polypeptide analog of hpG-CSF having one or more cysteine residues deleted or replaced by alanine or serine residues.

29. A non-naturally occurring polypeptide product of the expression in a procaryotic or eucaryotic host cell-of a polynucleotide according to claim 28.

30. A biologically functional plasmid or viral DNA vector including a DNA "sequence according to claim 28.

31. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to claim

32. A polypeptide according to claim 1 preceded by a methionine residue. An isolated polypeptide having the hematopoietic biological properties of naturally occurring pluripotent granulocyte colony-stimulating factor, said polypeptide 25 having an amino acid sequence selected from the polypeptide sequences set forth in Table VII, or any allelic variants, derivatives, deletion analogs, substitution analogs, or addition analogs thereof, and characterized by being non-naturally occurring and by S* being the product of procaryotic or eucaryotic expression of an exogenous DNA sequence.

34. A non-naturally occurring polypeptide consisting only of the amino acid sequence 1-174 set forth in Table VII. 73 A pharmaceutical composition comprising an effective amount of the polypeptide according to claim 32 or claim 34 and a pharmaceutically acceptable diluent, adjuvant or carrier.

36. An isolated polypeptide, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

37. A DNA sequence which codes upon expression in a procaryotic or eucaryotic host cell for a polypeptide product having at least a part of the primary structure and one or more of the biological properties of naturally-occurring pluripotent granulocyte colony-stimulating factor, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

38. A procaryotic or eucaryotic host cell transformed or transfected with a DNA sequence according to claim 6, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

39. A biologically functional plasmid or viral DNA vector including a DNA sequence according to claim 6, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or 20 examples.

40. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to claim 20, substantially as herein described with reference to 0• any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

41. A process for the production of a polypeptide having the primary structure of human pluripotent granulocyte colony-stimulating factor, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

42. A pharmaceutical composition comprising an effective amount of a polypeptide, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples. -74-

43. An isolated polypeptide having the hematopoietic biological properties of naturally occurring pluripotent granulocyte colony-stimulating factor, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

44. A non-naturally occurring polypeptide, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples. A process for the production of a polypeptide, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

46. Use of a polypeptide for the manufacture of a medicament for providing hematopoietic therapy to a mammal, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

47. Use of a polypeptide for the manufacture of a medicament for arresting proliferation of leukemic cells, substantially as herein described with reference to any "1 one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

48. A DNA sequence coding for a polypeptide analog ofhpG-CSF having one or more cysteine residues deleted or replaced by alanine or serine residues, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples.

49. A biologically functional plasmid or viral DNA vector including a DNA sequence, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples. 0 .o 50. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying figures and/or examples. DATED this 17 th day of September 2003 BALDWIN SHELSTON WATERS Attorneys for: KIRIN-AMGEN, INC